- DKMS-BMST continues to urge Indians to step up to be a potential lifesaver!

BENGALURU, India, Feb. 4, 2021 /PRNewswire/ -- February 4th is marked as World Cancer day every year. This day is observed to spread awareness about the disease and its increasing burden. In line with the theme for this year "Create a futurewithout cancer. The time to act isnow", DKMS BMST Foundation India, a non-profit organization with a mission to provide a second chance at life to blood cancer and blood disorder patients in India makes an appeal to people to come forward and register as potential blood stem cell donors.

On World Cancer Day 2021, DKMS is also celebrating a milestone of providing more than 90,000 blood cancer patients across 57 countries with a second chance at life, since it was founded almost 30 years ago in 1991. DKMS is an international non-profit organization that helps provide patients with lifesaving blood stem cell transplants. DKMS has presence in India, Germany, USA, Poland, UK, Chile, and South Africa.

Patrick Paul, CEO, DKMS BMST Foundation India, says, "DKMS is proud to be the world's leading donor center, accounting for nearly 30% of the total donor pool. While, this is a global milestone, when it comes to India, the fact is that the Indian donors are highly underrepresented in the global database. This is why it becomes difficult for doctors to find a matching blood stem cell donor for Indian patients. While DKMS has registered over 10.5 million donors and has provided over 90,000 patients with a second chance at life globally, it is critical to highlight that only over 43,000 Indian donors are part of this donor pool."

In India, every year, over one lakh people are diagnosed with a form of blood cancer and it remains one of the leading causes of cancer-related deaths among children. Most people are unaware that a life-threatening disease like blood cancer can be treated and in most of the cases, a stem cell transplant is the patient's only chance for survival. For instance, 15-year-old Maheer from Gujarat, India, is one of the blood cancer survivors who had received a lifesaving blood stem cell donation in 2012. He was able to find his matching blood stem cell donor, Dr. Sita, who hails from Germany. Today, he leads a normal, healthy and happy life. He is in grade 9 and loves to travel, read and swim.

Today, more than 37 million potential unrelated donors are listed worldwide with stem cell donor centers and registries, of which only 0.03% are Indians. Currently, in India, the biggest challenge is the lack of awareness about blood stem cell transplant and the importance of registering as a potential blood stem cell donor. The entire procedure is safe and secure. Once the blood stem cells are collected from a donor, they are infused into the patient through a transplant process which then moves through the bloodstream and settles in the bone marrow. These new blood stem cells begin to increase in numbers and produce red blood cells, white blood cells, and platelets, resulting in the replacement of the patient's diseased cells and that's how a blood cancer patient gets a second chance at life. This situation can only be improved by recruiting many more potential stem cell donors from India.

This World Cancer Day, one can take a pledge to become a potential lifesaver. Registration takes only 5 minutes. If one between 18 and 50 years and in good health, the first step to register as a blood stem cell donor by ordering the home swab kit at http://www.dkms-bmst.org/register.

SOURCE DKMS BMST Foundation India

More here:
World Cancer Day 2021: DKMS Announces The Milestone Of Giving 90,000 Blood Cancer Patients Worldwide A Second Chance At Life - PR Newswire India

Recommendation and review posted by Bethany Smith

As an athlete, Courtlynn Havard has always set goals for herself to improve her game whether on the soccer or softball field. She has worked toward those goals through hard work and perseverance.

Now her goals have shifted slightly.

Courtlynn, a sophomore at Franklin Parish High School, currently has two main goals: to beat aplastic anemia and paroxysmal nocturnal hemoglobinuria (PNH) and to help others.

Helping others for Courtlynn brightens her day, strengthens her and gives her hope for a better tomorrow.

From that desire to help others, the Havard family is sponsoring a bone marrow drive at Life Church in Winnsboro Feb. 20 from 10 a.m. until 2 p.m.

The drive will be administered by DKMS, an international nonprofit organization, whose goal is to find bone marrow donors for people like Havard.

It is simple as a swab in your cheek, said Jaimie Havard, Courtlynns mother. That could save a life. It only takes a few minutes and is so easy for you to give somebody a second chance on life.

Anyone 18-55 with good health can participate in the drive. Participates stay in their car, watch a video on their phone and fill out a short form, said Amy Roseman of DMKS.

They are given a kit with a swab for their cheeks. The whole process takes 7-10 minutes.

In October, Courtlynn went to the doctor with kidney stones. When doctors took her blood, they found her blood count was low.

Her mother and Courtlynn met with an oncologist who gave them disturbing news.

At first the oncologist thought it was leukemia, Jaimie said. You feel like your whole world is collapsing. I didnt know what to say or do. Courtlynn was devastated and crying. I was trying to be strong for her.

The Havards were then sent to LSU Health Shreveport. The medical professionals there performed a bone marrow biopsy and found she had aplastic anemia and PNH.

You never think it can be your child, Jaimie said. It is really an unbelievable, indescribable feeling.

Aplastic anemia is a condition that occurs when your body stops producing enough new blood cells, according to the Mayo Clinic. The condition leaves a person fatigued and more prone to infections and uncontrolled bleeding.

A rare and serious condition, aplastic anemia can develop at any age. It can occur suddenly, or it can come on slowly and worsen over time and can be mild or severe.

Treatment for aplastic anemia might include medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant.

PNH is a rare acquired, life-threatening disease of the blood. The disease is characterized by destruction of red blood cells (hemolytic anemia), blood clots (thrombosis), and impaired bone marrow function (not making enough of the three blood components).

PNH affects 1-1.5 persons per million of the population and is primarily a disease of younger adults. The median age of diagnosis is 35-40 years of age, with occasional cases diagnosed in childhood or adolescence. PNH is closely related to aplastic anemia.

Courtynns world use to evolve around sports, mud riding with her friends and being very social.

Now because of her weak immune system, she has to be careful and stay at home with her English Spaniel, Old Mack, and go to school virtually. Courtlynn talks to her friends via cell phone, computer and occasionally gets a visit from one that sits on her porch while she socially distances.

I missed my friends the most, Courtlynn said. I am one of those people that get up and go. I dont stay still.

She also goes to doctors whether it be locally to get her blood count tested, or Shreveport to receive platelets and blood or Memphis to St. Judes.

Saving people around the world

One thing that drives Courtlynn through this situation is keeping up with other kids situations, Jaimie said. There are so many stories out there of kids looking for bone marrow transplants.

The Feb. 20 bone marrow drive is a way Courtlynn and her family can help others.

DKMS has been finding matching bone marrow donors for 30 years. They are now in the United States, Germany, Poland, India and South Africa.

Sadly, only 2 percent of Americans have signed up as potential donors, Roseman said. We are hoping we will have really nice support for Courtlynn and the other patients looking for donors.

Reasons vary for the low percentage of potential donors, but Roseman attributes not knowing the need and ease of the process.

You fill out contact information, swab your cheeks and you are put in a data base that is only seen by medical teams searching for donors, Roseman said. We call it, youre a hero in waiting.

The biggest misconception is the donation of bone marrow if you are a match.

You are asked to donate stem cells from the blood stream, Roseman said. It is a very easy process. It is very similar to donating plasma or platelets and takes a morning or afternoon.

Blood is taken from one arm, and the blood is put back into the other arm, Roseman, said. Stem cells lost in the process will regenerate.

You have given someone a second chance in life, Roseman said.

A person may be asked to donate actual bone marrow if he or she is matched to a three year old or younger. This procedure is done in a hospital and takes less than an hour. DKMS pays for the hospital visit and time loss from work.

It is amazing to think about giving someone a second chance on life by giving up a just morning of your time, Roseman said.

A community comes together

The Franklin Parish community has come together in support of Courtlynn and the Havard family.

Boutique shops, individuals and restaurants have come together to raise money for her cause.

During the Feb. 20 bone marrow drive at Life Church a BBQ chicken plate lunch will be on sale for $10. T-shirts will also be on sale at the event. Keep up with all drives and Courtlynns journey on her Facebook page: Courtlynns Compass.

We have a really amazing group of friends and family that have come together, Jaimie said. Our local community has stepped up big time. Complete strangers are showing so much love and support for my baby. It speaks volumes for our little town we live in.

More here:
Helping others helps Havard through sickness | Community | hannapub.com - The Franklin Sun

Recommendation and review posted by Bethany Smith

Cynata Therapeutics (ASX: CYP), founded by two clever stem cell researchers and one wise Australian techpreneur, is in the process of developing a treatment for COVID-19.

Using its in-house stem cell technology Cymerus, the ASX-listed biotech hopes to treat one of the deadliest complications of COVID-19 -acute respiratory distress syndrome (ARDS).

In doing so Cynata would achieve what competitor Mesoblast (ASX: MSB) couldn't with FDA approval.

By deploying an industrialised approach to stem cell therapeutics, Cynata CEO Ross Macdonald (pictured) is confident the clinical trial process won't leave the company hamstrung.

In 1981 scientists discovered a way to derive embryonic stem cells from early mouse embryos.

The discovery thrilled scientists, and eventually led to the development of a method to do the same in lab-grown human embryos by 1998.

While there have been plenty of discussions surrounding the ethics of using of embryonic stem cells, these major scientific movements have pushed researchers to discover new and inventive ways of treating a whole raft of diseases and infections.

One such researcher, Dr Ian Dixon, saw potential for the use of mesenschymal stem cells (MSCs) - a type of stem cell that can differentiate into a variety of cell types enabling the treatment of many diseases and infections.

However there was still an obstacle to overcome: how do you mass produce enough cells needed to commercialise a treatment?

Luckily, two researchers at the University of Wisconson, Professor Igor Slukvin and Dr Maksym Vodyanik, had invented a biotechnological breakthrough called Cymerus.

The technology was able to do exactly what Dixon needed: the consistent manufacture of MSCs on an ultra-large scale; basically what Henry Ford did to the industrialisation of the auto industry, but for stem cells.

So in 2003 Dixon partnered with the two researchers to start Cynata - now an ASX-listed biotechnology company trialing a number of different treatments for a wide variety of ailments.

Most recently, Cynata's focus has been on developing a treatment for a complication of COVID-19 called acute respiratory distress syndrome (ARDS).

The complication ravages COVID-19 infected patients, destroying their organs through what is known as a cytokine storm. The complication is estimated to kill up to half of COVID-19 patients that suffer from it.

Melbourne-based Cynata is currently in the very early stages of its investigation into whether its MSCs will be able to treat the coronavirus complication overwhelming hospitals globally.

If this all sounds familiar, you might be thinking of another ASX-listed biotech called Mesoblast (ASX: MSB).

In March last year Mesoblast, also based in Melbourne, saw its shares surge after announcing plans to evaluate its stem cell treatment solutions on COVID-19 patients.

The group commenced the arduous clinical trial process to see if its remestemcel-L therapy could treat ARDS by using bone marrow aspirate from healthy donors - a similar approach the company had already taken to treat a condition many suffer from after receiving bone marrow transplants.

Mesoblast was riding high on the ASX following positive announcements surrounding the clinical traila process, especially back in April 2020 when a trial at New York City's Mt Sinai hospital found its remestemcel-L therpay achieved "remarkable" results.

Serious attention gathered around Mesoblast, with the company even securing $138 in funds from investors to continue its important research.

The company went so far as to sign a commercialisation deal for the COVID-19 treatment with Novartis, and the US Food and Drugs Administration (FDA) fast tracked the approvals process for the potential game-changing treatment.

However, in December 2020, Mesoblast hit a stumbling block.

Mesoblast's COVID-19 treatment flunked the test - its remestemcel-L therapy failed to show a lower mortality rate for patients in the prescribed 30-day timeframe of treatment.

At that point Cynata had commenced research into its own ARDS treatment. But did Mesoblast's failure unnerve Cynata CEO Ross Macdonald? Not a chance.

"I'm more confident that our trial will be successful where theirs was a failure," Macdonald said.

"If you use a process like we have developed - we don't rely on multiple different [stem cell] donations. You start with exactly the same material every time."

To explain, Macdonald used the analogy of a local caf; you normally expect a coffee from one caf to taste more or less exactly the same every time you go there - the same beans are used every time.

Whereas Macdonald said Mesoblast's process is like going to the same caf every day, but each visit they use different beans from a different supplier which leads to inconsistency in taste and flavour.

Cynata's approach with its MSCs is in line with the first example - what you get the first time from them will be replicated in each and every dose of the drug - while MSB's is like the latter.

"Yes, you still got the coffee, but the experience of the taste is totally different than it was yesterday," he said.

"The FDA said to Mesoblast, well you've got a manufacturing problem that is reliant upon multiple donors prepared to donate bone marrow and that is flawed.

"So with that in mind it's perhaps not surprising that they had a pretty disappointing result in the clinical trials."

Additionally, Macdonald said the initial investor reactions to MSB's early COVID-19 trail results were overblown.

"The initial data from their trial that got everybody excited was, in my view, quite flawed, because they said "look at how many patients are dying in intensive care units with COVID compared the patients that we treated," he said.

"But the reality of the situation was quite different. The control group at that time - the death rate was way, way higher than you would typically see for ARDS, whether its COVID or anything else. And it was simply because of the chaos that existed in intensive care units in New York in the first wave.

"So we think that the initial enthusiasm was perhaps a little misguided."

When asked why Mesoblast is receiving so much attention compared to Cynata, especially considering the above, Macdonald said it was simply because MSB is bigger and has been around for longer. For context, MSB has a market capitalisation of $1.46 billion, whereas Cynata's is just $94.56 million.

"I'd love to know why there is less attention, and how we can get our market cap above a billion dollars," joked Macdonald.

"I think the answer though is that they've been around for a lot longer than we have, they have spent a hell of a lot more money than we've spent - their monthly spend is more than we've spent for pretty much our entire existence.

"But I think the fundamental reason why is that data drives value in biotech, so the more clinical data you generate that shows your product works, the more attention you attract from investors."

That's not to say Cynata is being totally ignored in favour of the larger Mesoblast.

The company secured a $15 million placement led by $10 million from healthcare investor BioScience Managers in December.

The funds will be used to expand Cynata's clinical development pipeline and scale their operations in Australia.

As such, the company is preparing to expand its clinical development pipeline to include idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers.

"So we're starting to garner that attention now that says two things - one, cell therapies are definitely a medical revolution and two, Cynata is part of that new generation of companies," Macdonald said.

As for the company's pipeline, in addition to the COVID treatment trials, Cynata is planning on launching three new clinical candidates that will get under way this year.

There's also Cynata's osteoarthritis trial, which Macdonald describes as significant for the biotech company; with 2 million patients in Australia and 30 million in the United States the company is hoping to tap into an $11 billion plus addressable market.

"It will ultimately show whether MSCs are useful in that particularly devastating condition," he said.

"It doesn't just affect people who want to go and play golf or tennis, it affects, particularly manual labourers who can no longer work.

"So the cost to the economy of osteoarthritis is quite significant, which is of course one of the reasons why the Australian Government is funding this trial."

Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.

Business News Australia

The rest is here:
Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia

Recommendation and review posted by Bethany Smith

The anti-emetic agent metoclopramide blocked CD93 signaling in cell culture and delayed leukemia development in mice, according to data from a preclinical study published in Cell Reports. The results indicate that CD93 signaling, which is an important regulator of self-renewal and proliferation of murine and human leukemia stem cells (LSCs), could be a potential therapeutic target for the elimination of LSCs in chronic myeloid leukemia (CML).

To characterize the function of CD93 in CML, the researchers first demonstrated that all subsets of LSCs expressed CD93 while more differentiated leukemia granulocytes did not. Though CD93 was shown to encourage self-renewal and proliferation of murine and human LSCs, it notably had no such effect on hematopoietic stem cells.

In an experiment, the investigators injected mice with LSCs that were either proficient or deficient in CD93. Mice with CD93-deficient LSCs were found to incorporate bromodeoxyuridine, which is used to detect proliferating cells, at a lower rate than mice with CD93-proficient LSCs. The finding suggests that proliferation of LSCs is impaired when CD93 is absent.

Next, a drug library was used to screen for compounds that could block CD93 signaling. Among the 240 compounds evaluated in vitro, 10 blocked CD93 signaling; one of the compounds was the anti-emetic agent metoclopramide.

Mice were then treated with either vehicle or metoclopramide. Notably, metoclopramide-treated mice had delayed leukemia development and lived longer than vehicle-treated mice. Among the metoclopramide-receiving mice, most genes were downregulated in the LSCs, particularly genes that promote stem cell maintenance and myeloid differentiation, cell proliferation and survival, response to cytokine signaling, and gene expression.

In vitro exposure to metoclopramide was found to disrupt colony formation in human bone marrow CML stem/progenitor cells. A control experiment showed that metoclopramide had no effect on hematopoietic stem/progenitor cells from humans with healthy bone marrow.

The study authors reasoned that because metoclopramide is a very well-tolerated and cheap anti-emetic drug, its LSC-eradicating activity in patients with CML can be directly tested in clinical drug repurposing studies.

Reference

Riether C, Radpour B, Kallen NM, et al. Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. Cell Rep. 2021;34(4):108663. doi:10.1016/j.celrep.2020.108663

Read the original here:
Anti-Emetic Drug Effectively Blocks CD93 Signaling in Preclinical Evaluations, Suggesting Suitability in CML - Cancer Therapy Advisor

Recommendation and review posted by Bethany Smith

World Cancer Day 2021: It is observed on 4 February every year and this year the theme is "I Am and I Will".The campaign shows that our actions have an impact on everyone around us, within our neighbourhoods, communities, and cities. This year is a reminder of the enduring power of cooperation and collective action i.e. together, all our actions matter.

What are Blood Cancers?

It is a type of cancer that affects blood cells and affects the production and function of blood cells.

This type of cancer starts in the bone marrow which is the main source of blood production.

It occurs when abnormal blood cells start growing out of control and interrupt the function of normal blood cells that fight off infection and produce new blood cells.

World Cancer Day 2021: Current Theme, History and Key Facts

Blood Cancer: Types

Mainly, there are three types of blood cancers namely leukemia, lymphoma, and myeloma.

Leukemia

It is a blood cancer that originates in the blood and bone marrow. It is caused by the rapid production of abnormal white blood cells and interferes with the bone marrow's ability to make red blood cells and platelets. These high numbers of abnormal white blood cells are not able to fight infection.

Lymphoma

This type of blood cancer affects the lymphatic system, which removes excess fluids from the body and produces immune cells. As we know that lymphocytes are a type of white blood cell that fights infection. Therefore, abnormal lymphocytes become lymphoma cells that multiply and collect in the lymph nodes and other tissues. And over time, these cancerous cells impair the immune system of the body.

Myeloma

It is a type of blood cancer that begins in the plasma cells of blood which is a type of white blood cell made in the bone marrow. Plasma cells are white blood cells that produce antibodies to fight against infection and disease in the body. So, myeloma cells prevent the normal production of antibodies which make the immune system weak and susceptible to infection.

Blood Cancer: Symptoms

Loss of appetite, nausea

Fever, chills

Night sweats

Persistent fatigue, weakness

Unexplained weight loss

Bone/joint pain

Shortness of breath

Abdominal discomfort

Frequent infections

Itchy skin or skin rash

Swollen lymph nodes in the neck, underarms or groin

Delirium and confusion

Decreased urination and difficulty while urinating

What is High Grade Metastatic Cancer?

Blood Cancer: Treatment

On the type of cancer, treatment depends and how fast the cancer is progressing, where cancer has spread, and other factors. Some common treatment for blood cancer are:

Chemotherapy: In this anticancer cancer drugs are provided to the patient to interfere with and stop the growth of cancer cells in the body. In blood cancer, in chemotherapy treatment, sometimes several drugs are given together in a set regimen. This treatment may also be given before a stem cell transplant.

Radiation therapy: In this type of cancer treatment high-energy rays are given to kill cancer cells. It may also be given before a stem cell transplant.

Stem cell transplantation: In this type of treatment, healthy stem cells are infused into the patient body to help resume healthy blood production following therapy to destroy malignant blood cells. Stem cells may be collected from the bone marrow, circulating blood, and umbilical cord blood.

Blood Cancer in India

In India, over 20,000 new cases of childhood blood cancer are diagnosed every year of which nearly 15,000 of those cases are leukemia as per Globocan 2020.

The most common type of blood cancer is leukemia that affects children and teens (0-19 years) and one of the leading causes of death.

As per some studies, India ranks 3rd highest in reported cases of Blood Cancer after the US and China. Several factors are responsible like low accessibility of affordable healthcare in rural areas, lack of awareness and education on Blood Cancer, etc.

So, now you may have come to know about the blood cancer, types, symptoms, treatment, etc.

GK Questions and Answers on Types of Cancers

See original here:
World Cancer Day 2021: What are Blood Cancers, Types, Symptoms, Treatment and data in India? - Jagran Josh

Recommendation and review posted by Bethany Smith

Dave Asprey  |  Photo Credit: Twitter

A man who is determined to live until he is 180 years old says that his bizarre methods will soon be as popular as mobile phones. American millionaire tech entrepreneur Dave Asprey, 47, believes he will live to the year 2153 'at least' by using techniques such as sitting in a cold cryotherapy chamber and intermittent-fasting.

Dave coined the term 'Biohacking' to describe his methods of turning back the biological clock.

He got parts of his bone marrow removed to have the stem cells injected back into his body for $25,000 (Rs 18 lakh).

He speculated that people who are under 40 years of age will be "happy and highly functional" at 100 after applying his methods.

When This Morning's Holly Willoughby asked him why he wants to live so long, he replied, "I'm curious, I think there's a lot of things we can fix and improve in the world and I don't feel like I'm at all done yet."

Dave believes that he won't be the only one to be live for so long.

"The things I am working to pioneer, some of them are expensive, some of them are free like fasting. This will be like cell phones, everyone has cell phones - everyone will have anti-ageing. Change can happen rapidly in society," he said. "There will be many people who are under 40 right now who [will be] walking around under their own power, perfectly happy, highly functional, who are more than 100 years old."

Dave has spent an estimated $1 million on techniques and hacks to try and improve his body's overall functioning.

He added, "I set myself up to have much less inflammation than most people do, by controlling what I eat and how I sleep and a lot of other anti-ageing treatments."

He explained why he re-introduced his stem cells in his body, saying, "When we're young, we have a ton of stem cells and we heal like young people. As we age our stem cells get exhausted, so I do things like intermittent fasting which give me more stem cells and then I take my own stem cells and move them around the body so I heal and move like a young person."

Dave also believes in the benefits of cryotherapy, also known as cold therapy, which is the use of low temperatures in medical therapy to treat a variety of tissue lesions. He has been having cold showers for over ten years.

Another technique that Dave uses to live a long life is intermittent fasting, which involves restricting times that you eat meals to create periods of fasting over a certain period.

Follow this link:
Man who wants to live for 180 years spends Rs 18 lakh to re-inject his own stem cells - Times Now

Recommendation and review posted by Bethany Smith

India Stem Cell Market to surpass huge revenue of USD 1.27 Billion at CAGR +13% by 2028.

Stem cell therapy in India helps in treating several diseases, including leukaemia, lymphoma, thalassemia, Parkinsons, Alzheimers, stroke, cerebral palsy, spinal cord injury, muscular dystrophy, etc. Stem cell therapy in India has shown promising results in India and as well as all over the world.

In comparison, in India it costs INR 10-20 lakh in private hospitals, while in government hospitals it is much cheaper INR 3-6 lakh depending on the type of procedure, he said

On average, private banking of stem cells derived from cord blood costs INR 50,000-70,000. Banks claim to freeze the cells in liquid nitrogen so that it can be used up to 20 years from the date of preservation.

Researchers hope stem cells will one day be effective in the treatment of many medical conditions and diseases. But unproven stem cell treatments can be unsafe so get all of the facts if youre considering any treatment. Stem cells have been called everything from cure-alls to miracle treatments.

Request a sample copy of report @ https://www.reportconsultant.com/request_sample.php?id=80360

Key players profiled in the report includes:

Thermofisher Scientific India Pvt. Ltd., Pluristem Technologies Ltd., Becton Dickinson Private Limited, Stem Cell Technologies India Pvt. Ltd., Merck Lifescience Pvt. Ltd., Cordlife India Pvt. Ltd., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Private Limited, Stempeutics Research Private Limited, ReeLabs Private Limited, CryoSave, Indu Stem Cell Bank, Path Care Labs Pvt

The aim of the report is to equip relevant players in deciphering essential cues about the various real-time market based developments, also drawing significant references from historical data, to eventually present a highly effective market forecast and prediction, favoring sustainable stance and impeccable revenue flow despite challenges such as sudden pandemic, interrupted production and disrupted sales channel in the India Stem Cell market.

Market segments on the basis of:

This research report is an amalgamation of all relevant data pertaining to historic and current market specific information that systematically decide the future growth prospects of the India Stem Cell market. This section of the report further aims to enlighten report readers about the decisive developments and catastrophic implications caused by an unprecedented incident such as the pandemic that has visibly rendered unparalleled implications across the market.

This report is well documented to present crucial analytical review affecting the India Stem Cell market amidst COVID-19 outrage. The report is so designed to lend versatile understanding about various market influencers encompassing a thorough barrier analysis as well as an opportunity mapping that together decide the upcoming growth trajectory of the market. In the light of the lingering COVID-19 pandemic, this mindfully drafted research offering is in complete sync with the current ongoing market developments as well as challenges that together render tangible influence upon the holistic growth trajectory of the India Stem Cell market.

Besides presenting a discerning overview of the historical and current market specific developments, inclined to aid a future-ready business decision, this well-compiled research report on the India Stem Cell market also presents vital details on various industry best practices comprising SWOT and PESTEL analysis to adequately locate and maneuver profit scope. Therefore, to enable and influence a flawless market-specific business decision, aligning with the best industry practices, this specific research report on the market also lends a systematic rundown on vital growth triggering elements comprising market opportunities, persistent market obstacles and challenges, also featuring a comprehensive outlook of various drivers and threats that eventually influence the growth trajectory in the India Stem Cell market.

Get upto 40% Discount available on this Report @ https://www.reportconsultant.com/ask_for_discount.php?id=80360

India Stem Cell Geographical Segmentation Includes:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of L.A.)

Middle East and Africa (Turkey, GCC, Rest of Middle East)

Some Major TOC Points:

Chapter 1. Report Overview

Chapter 2. Growth Trends

Chapter 3. Market Share by Key Players

Chapter 4. Breakdown Data by Type and Application

Chapter 5. Market by End Users/Application

Chapter 6. COVID-19 Outbreak: India Stem Cell Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Force

And More

In this latest research publication a thorough overview of the current market scenario has been portrayed, in a bid to aid market participants, stakeholders, research analysts, industry veterans and the like to borrow insightful cues from this ready-to-use market research report, thus influencing a definitive business discretion. The report in its subsequent sections also portrays a detailed overview of competition spectrum, profiling leading players and their mindful business decisions, influencing growth in the India Stem Cell market.

About Us:

Report Consultant A worldwide pacesetter in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly by taking calculative risks leading to lucrative business in the ever-changing market. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies.

Our research reports will give you the most realistic and incomparable experience of revolutionary market solutions. We have effectively steered business all over the world through our market research reports with our predictive nature and are exceptionally positioned to lead digital transformations. Thus, we craft greater value for clients by presenting progressive opportunities in the futuristic market.

Contact us:

Riaana Singh

(Report Consultant)

sales@reportconsultant.com

http://www.reportconsultant.com

See the original post:
India Stem Cell Market speedy growth at US$ 1.27 Bn by 2028 with Thermofisher Scientific India, Pluristem Technologies, Becton Dickinson Private...

Recommendation and review posted by Bethany Smith

Introduction

Osteonecrosis of the femoral head is a progressive disorder that causes pain and often progresses to hip joint collapse, finally resulting in disabling arthritis.1,2 It occurs between 30 to 50 years of age, and prevails at a relatively younger age in Asians compared to their western counterparts.3 It is estimated that approximately 20,00030,000 new cases of osteonecrosis are diagnosed in the United States each year, accounting for 10% of total hip arthroplasties performed.4 The Indian Society of Hip and Knee Surgeons has reported that more than 50% of all hip replacements in India are performed for osteonecrosis.5 Many studies have reported osteonecrosis to be more prevalent in men compared to women (3 or 5:1).3 The underlying pathophysiology of osteonecrosis remains unclear; however, it is multifactorial and several traumatic and nontraumatic etiological factors may contribute to its development. Traumatic events that may cause osteonecrosis include femoral neck/head fracture, hip dislocation, or slipped capital femoral epiphysis. Nontraumatic factors include use of steroids, alcoholism, metabolic disorders such as Cushings syndrome, and inherited disorders such as sickle cell disease.6,7 Besides the known traumatic and nontraumatic causes, some cases of osteonecrosis are idiopathic.1,8

Osteonecrosis of the femoral head may progress to secondary arthritis, and degeneration of articulating surface from advanced osteonecrosis necessitates total hip arthroplasty (THA). A primary treatment target of osteonecrosis of femoral head is to delay/prevent progression to osteoarthritis. Core decompression (CD) is the most widely used procedure in clinical practice; however, it has shown poor clinical outcomes, with up to 40% of patients having to undergo THA despite undergoing core decompression procedure.8 Therefore, a more pathophysiological approach may be required to treat osteonecrosis of femoral head. Osteonecrosis is characterized by a reduction in the osteogenic progenitor cells, an increase in osteoblast death, and altered intramedullary vascular supply due to trauma.1 It was observed that the number and function of mesenchymal cells in hematopoietic tissue and stroma of the bone marrow decreased in osteonecrosis patients.2 This observation indicated potential for using bone marrow stromal cells for the treatment of osteonecrosis, and consequently, several clinical studies have demonstrated encouraging results.2 A meta-analysis also showed that treatment with cell therapy compared to core decompression alone increased Harris hip score, decreased necrotic area of femoral head and collapse of femoral head, and reduced THA conversion rate.9 However, a recent randomized study has shown that bone marrow cell implantation in addition to core decompression did not improve THA conversion rate in patients with grade 3 osteonecrosis.10 The ideal treatment goal for osteonecrosis is to facilitate new bone formation in the place of dead bone that can provide pain relief, cease disease progression, prevent joint collapse, and preserve the joint. The fact thatbone marrow aspirate consists of mesenchymal stem cells raised a possibility if bone marrow cells could be differentiated into bone forming cells or osteoblasts and characterized by bone alkaline phosphatase. In a randomized trial, autologous osteoblast implantation was shown to significantly delay the evolution to subchondral fracture and reduce pain compared to bone marrow aspirate.11

OSSGROW (Regrow Biosciences Pvt Ltd., Mumbai, India) is a commercially available technology that involves implantation of autologous adult live-cultured osteoblasts (AALCO) derived from mesenchymal stem cells sourced from the bone marrow aspirate for osteonecrosis of the hip that received conditional marketing approval in India in March 2017.12 Here, we evaluated the efficacy of OSSGROW implantation technique by assessing retrospective data from patients with osteonecrosis who underwent the procedure. We also evaluated the correlation between Ficat-Arlet stages of osteonecrosis and clinical outcomes of the AALCO implantation procedure.

This retrospective, observational, non-comparative study was conducted at 37 centers in India. We retrospectively reviewed the data of patients with osteonecrosis of the femoral head who had undergone OSSGROW (AALCO) from 2010 to 2015. Key inclusion criteria were patients aged 12 years with a confirmed diagnosis of osteonecrosis in one or both hip joints who had undergone AALCO implantation. Diagnosis, analysis, and classification of osteonecrosis were done according to Ficat-Arlet based on radiography, computed tomography (CT) scans, and magnetic resonance imaging (MRI) findings. Patients whose medical records were not complete or were lost to follow-up were excluded from the study.

The protocol was approved by the Institutional Ethics Committee - Regrow Biosciences Pvt Ltd. and as this study was a retrospective study, informed consent was not required to review medical records. We also sought permission from the head of the institutes/departments before data collection. Patient data confidentiality was maintained in this study.

All the patients had undergone AALCO implantation on the recommendation of their consulting orthopedic surgeon after having received an explanation of the complications of osteonecrosis, the therapeutic options available, and the risks involved with the implantation procedure. Osteoblasts from patients were obtained from bone marrow aspiration from the posterior/superior iliac crest. Mesenchymal stem cells from the bone marrow were isolated and differentiated ex vivo into osteoblasts. Osteoblasts were then cultured for approximately 4 weeks under stringent laboratory conditions and multiplied up to 48 million osteoblasts (Figure 1). The cultured cells were implanted using a gel (Tisseel kit from Baxter) at the site of osteonecrosis through a minimally invasive surgery in a 3-step procedure: core decompression, curettage, and injection of osteoblasts (Figure 2).

Figure 1 Microscopic image of osteoblast in culture used for the final cell product before cell implantation.

Figure 2 Steps of osteoblasts implantation. (A) Step 1 Insertion of guide wire in center of lesion as identified on the MRI. (B) Step 2 Guide wire and 8mm cannulated drill for core decompression. The entry point of the guide wire is near the vastus ridge, to prevent a fracture due to stress-riser, greater width of femur and faster healing due to cancellous bone. (C) Step 3 Curettage: a variety of angulated curettes is used to do forage (curettage to remove necrotic bone). This bone is sent for biopsy.

Patients were operated on under spinal anesthesia. Core decompression tunnels were created into the subchondral necrotic lesion of the femoral head, approximately 23 mm away from the joint cartilage, by using 2.0-mm K-wires under fluoroscopic guidance through the greater trochanter and the femoral neck, and over drilled using trephine was performed by the centrally positioned K-wire. Cultured osteoblasts were injected following the curettage, and necrotic tissues were removed.

The patients had to undergo appropriate rehabilitation therapy after the implantation, which included complete bed-rest for 4 weeks post-implantation. After 4 weeks, passive lower limb exercises were performed for 2 weeks following post-implantation. Accordingly, non-weight bearing, partial weight bearing, and full weight bearing exercises were suggested as per the study protocol. Descriptive demographic and clinical data recorded before and after the procedure were collected from patient records. Past medical history, concomitant medications, and surgical treatments undertaken before and after the AALCO were recorded. Pre-existing risk factors for osteonecrosis such as steroid intake, alcohol consumption, comorbid conditions, or trauma were also noted.

Improvement in functional capacity and pain reduction were evaluated using Harris Hip Score (HHS) and visual analog scale (VAS) respectively at the time of pre- and post-operative consultations. Continued use of steroids or alcohol consumption after undergoing the AALCO implantation was recorded. The main outcome of the study was the need for THA (THA conversion rate). Based on these parameters, the treatment outcome was determined to be either improved (better score after AALCO implantation), stable (same condition as before AALCO implantation), or progressive (worse scores following AALCO implantation).

Continuous and quantitative variables were summarized using descriptive statistics and compared using Students t-test or nonparametric test, as applicable. Categorical data were presented as frequency count (n) and percentages (%) and were compared using the 2 test or Fishers exact test. P-values <0.05 were considered significant. All analyses were performed using the SPSS version 10.0.

Data from 64 patients were collected and analyzed as per the study protocol, and 101 hip joints were assessed. The age of patients ranged from 1270 years and BMI ranged from 20.632 kg/m2. The majority of the patients were men (79.7%). The mean duration since diagnosis of osteonecrosis was 7.4 1.6 years and the mean duration of AALCO treatment was 6.3 1.4 years (Table 1). Unilateral involvement of the hip joint was seen in 42.2% of cases. Bilateral involvement of hip joints was seen in 57.8% of patients. The majority of hips diagnosed were grade III (42.1%) and grade IV osteonecrosis (10.5%). While the exact cause for osteonecrosis was not known (idiopathic) in 25% of patients, 35.9% of cases were linked to steroid use and 26.6% to alcohol abuse. Records of concomitant medications revealed that 91.9% of patients were on analgesics, 8.1% were on ayurvedic treatment, and 1 patient took bisphosphonate.

Table 1 Demographic Characteristics

A total of 98 hip joints were assessed as data of 3 patients were not available for changes in mean VAS scores (improvement in pain), before and after the AALCO implantation. As shown in Figure 3A, the mean VAS score reduced significantly after a mean 6.3 years of AALCO treatment compared to the baseline (32.2 32.1 vs 58.8 13.8; mean difference: 26.5 35.2, p = 0.001) indicating significant improvement in pain. Similarly, HHS also improved post-operatively (47.1 12.3 vs 63.7 27.7; mean difference: 16.7 28.7, p = 0.001) showing functional improvement of patients. We categorized patients based on their HSS score (<70: poor, 7080: fair, 8090: good, 90100: excellent). At baseline, 96 hips (98%) had HSS score of <70, each of the two remaining hips had scores of <80 and <90, respectively. Improvement in HSS scores was seen at follow-up with 42 hips (43.3%) with HSS <70, 11 (11.3%) with 7080, 26 (26.8%) with 8090, and 18 (18.6%) with HSS scores of 90100.

Figure 3 (A) Changes in visual analog scale (VAS) and Harris hip scores. (B) Need for hip replacement surgery in different grades of osteonecrosis. (Osteonecrosis graded according to Association Research Circulation Osseous criteria).

The mean follow-up period since diagnosis of osteonecrosis was 6.3 years (range 49 years). Following AALCO treatment, 29 (28.7%) hips underwent THA, indicating that AALCO treatment could prevent and delay THA for 71.3% of hips. The mean time to THA was 3.2 2.0 years (range: 19 years). A total of 9 (39.1%) grade II, 11 (47.8%) grade III, and 3 (13%) grade IV hip joints required THA surgery (Figure 3B). In other words, AALCO treatment could delay THA for up to 3 years in 80% of hips in early stage osteonecrosis (Grades I and II) and 72% of hips in late stage osteonecrosis (Grades III and IV). Univariate analysis showed that the age of the patient, BMI, gender of patients, the side of osteonecrosis, and duration of disease had no effect on the clinical success of the procedure. Following AALCO treatment, 35.9% of patients continued using steroids and 29.7% continued with alcohol consumption. Of the total 29 hip joints that required surgery at follow-up, 20.7% and 41.4% had an associated etiology of alcohol consumption and steroid intake, respectively (Figure 4A). Overall, a significantly greater number of patients with underlying etiologies of alcohol consumption, smoking, or taking steroids required THA compared to those without these etiologies (14 [37.8%] vs 3 [11.1%], p = 0.017).

Figure 4 (A) Need for hip replacement stratified as per etiology of osteonecrosis. (B) Overall outcome stratified as per the grades of osteonecrosis.

Abbreviations: RA, rheumatoid arthritis; SLE, systemic lupus erythematous.

Based on the pre- and post-operative data, the condition of 65.6% of patients improved and 1.6% remained stable following AALCO treatment. Overall, the condition of 65.9% of hips (56/85) in grade I to grade III improved (Figure 4B). For quick reference, the pre- and post-operative radiograph images for a given patient are presented in Figure 5.

Figure 5 Pre- and posttransplantation MRI and X-ray images (A): pre-operative MRI (male patient [35 years]): Ficat and Arlet Stage II B with a subchondral fracture of right hip with a large anterolateral lesion(arrow) involving more than 40% of femoral head and less than 2mm depression at high risk of collapse. Etiology is post steroid AVN. (B) Post-operative MRI at 5 months post-surgery. (C) Post-operative X-ray at 4 years after surgery; anteroposterior (AP) view and lateral view.

We retrospectively studied the clinical outcomes of AALCO treatment. Our results showed that there was a reduction in pain and improvement in joint function following AALCO implantation, as was evident from a statistically significant reduction in the mean VAS score and increase in the HHS score. Of all the hips that underwent the AALCO implantation, 60% improved and 38% worsened with a THA conversion rate of 28%.

AALCO is a minimally invasive, surgical 3-step procedure with each step contributing significantly to the overall effectiveness of the treatment. The first step is core decompression that reduces pressure allowing increased blood flow. In the second step, the necrotic bone is debrided by a curette that promotes new bone formation. The third and most important step is implantation of osteoblasts that form new bone. The THA conversion rate is reported lower with core decompression compared to natural progression of disease, but approximately 40% of patients still required THA.8 Bone marrow cell therapy was shown to improve the THA conversion rate further.9 In a recent randomized trial, implantation of autologous bone marrow aspirate concentrate did not show any improvement in patients with grade 3 osteonecrosis.10 In our study, AALCO implantation avoided THA in 72% of hips in late grade osteonecrosis, suggesting that the technique may even benefit patients in advanced stages of disease; however, our results are limited by the relatively small numbers of patients belonging to each stage.

The differences in the THA conversion may not be directly comparable to those with others may be due to the diversity in the presentation of patients, differences in the follow-up period, or the AALCO technique.13,14 The THA conversion rate certainly remains low with AALCO treatment compared to 75% THA conversion rate reported in patients with natural progression to osteoarthritis resulting from osteonecrosis of the femoral head.15,16 A randomized study found autologous osteoblastic cells implantation to be more efficacious than bone marrow implantation as an adjunct to core decompression. The disease progression rate was found to be 20% in patients who had undergone autologous osteoblasts implantation vs 47% in patients in the bone marrow implantation group.11 Bone alkaline phosphatase-characterized osteoblasts have better regenerative potential compared to heterogeneous bone marrow cells.17,18 Use of these characterized cells could explain the favorable outcomes of AALCO implantation in our study.

Intake of alcohol and/or steroids is known to adversely affect bone renewal by causing an imbalance between the normal progenitor cells and the fat-storing bone marrow progenitor cells.1,19,20 The latter phenotype also leads to fat embolism and arteriosclerosis reducing the blood supply to necrotic tissues.1,19,20 In our study, alcohol and steroid intake were associated with occurrence of osteonecrosis of the femoral head in more than a quarter of patients. These results highlight the adverse impact of alcohol and steroid intake on the progression of osteonecrosis that is already evident in the literature in the pathogenesis of osteonecrosis.2125 As expected, THA conversion rate was also higher among patients who consumed alcohol and/or used steroids compared to those who did not in our study, signifying the adverse impact of alcohol and steroids on the AALCO treatment outcomes. However, a consensus on the specific mechanisms leading to these observations is yet to be reached.

A major limitation of our study was the retrospective data collection, and the lack of assessments of radiographic progression of the affected hips.

The results of this study substantiate the therapeutic potential for AALCO in improving clinical outcomes in terms of pain and functional activity, and reducing the risk of disease progression and the need for THA in patients with osteonecrosis. However, this study was limited by the small sample size and the retrospective data collection limiting the power of study for some subgroup comparisons. Further, clinical studies and long-term trials are warranted to confirm the findings of this study.

Authors acknowledge CBCC Global Research for providing medical writing and submission support funded by Regrow Biosciences Pvt. Ltd.

The authors report no conflicts of interest in this work.

1. Hernigou P, Poignard A, Zilber S, Rouard H. Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J Orthop. 2009;43(1):4045. doi:10.4103/0019-5413.45322

2. Gangji V, Hauzeur J-P, Matos C, De Maertelaer V, Toungouz M, Lambermont M. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells: a pilot study. J Bone Joint Surg Am. 2004;86(6):11531160. doi:10.2106/00004623-200406000-00006

3. Vardhan H, Tripathy SK, Sen RK, Aggarwal S, Goyal T. Epidemiological profile of femoral head osteonecrosis in the North Indian population. Indian J Orthop. 2018;52(2):140146. doi:10.4103/ortho.IJOrtho_292_16

4. Moya-Angeler J, Gianakos AL, Villa JC, Ni A, Lane JM. Current concepts on osteonecrosis of the femoral head. World J Orthop. 2015;6(8):590601. doi:10.5312/wjo.v6.i8.590

5. ISHKS registry. Available from: http://www.ishks.com/pdf/ISHKS-registry-2019.pdf. Accessed December 17, 2020. 2019.

6. Xie XH, Wang XL, Yang HL, Zhao DW, Qin L. Steroid-associated osteonecrosis: epidemiology, pathophysiology, animal model, prevention, and potential treatments (an overview). J Orthop Translat. 2015;3(2):5870. doi:10.1016/j.jot.2014.12.002

7. Jaffr C, Rochefort GY. Alcohol-induced Osteonecrosisdose and duration effects. Int J Exp Pathol. 2012;93(1):7879. doi:10.1111/j.1365-2613.2011.00798_1.x

8. Houdek MT, Wyles CC, Martin JR, Sierra RJ. Stem cell treatment for avascular necrosis of the femoral head: current perspectives. Stem Cells Cloning. 2014;7:6570. doi:10.2147/SCCAA.S36584

9. Xu S, Zhang L, Jin H, et al. Autologous stem cells combined core decompression for treatment of avascular necrosis of the femoral head: a systematic meta-analysis. Biomed Res Int. 2017;2017:6136205. doi:10.1155/2017/6136205

10. Hauzeur JP, De Maertelaer V, Baudoux E, Malaise M, Beguin Y, Gangji V. Inefficacy of autologous bone marrow concentrate in stage three osteonecrosis: a randomized controlled double-blind trial. Int Orthop. 2018;42(7):14291435. doi:10.1007/s00264-017-3650-8

11. Hauzeur JP, Toungouz M, Lechanteur C, et al. Autologous osteoblastic cells (PREOBy) versus concentrated bone marrow implantation in osteonecrosis of the femoral head: a randomized study. Revue de Chirurgie Orthopdique et Traumatologique. 2016;102(7):S73. doi:10.1016/j.rcot.2016.08.002

12. Cuende N, Rasko JEJ, Koh MB, Dominici M, Ikonomou L. Cell, tissue and gene products with marketing authorization in 2018 worldwide. Cytotherapy. 2018;20(11):14011413. doi:10.1016/j.jcyt.2018.09.010

13. Pepke W, Kasten P, Beckmann NA, Janicki P, Egermann M. Core decompression and autologous bone marrow concentrate for treatment of femoral head osteonecrosis: a randomized prospective study. Orthop Rev (Pavia). 2016;8(1):6162. doi:10.4081/or.2016.6162

14. Zhao D, Cui D, Wang B, et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone. 2012;50(1):325330. doi:10.1016/j.bone.2011.11.002

15. Hernigou P, Habibi A, Bachir D, Galacteros F. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg Am. 2006;88(12):25652572. doi:10.2106/00004623-200612000-00002

16. Tomaru Y, Yoshioka T, Sugaya H, et al. Ten-year results of concentrated autologous bone marrow aspirate transplantation for osteonecrosis of the femoral head: a retrospective study. BMC Musculoskelet Disord. 2019;20(1):410. doi:10.1186/s12891-019-2797-4

17. Birmingham E, Niebur G, McHugh PE. Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte and osteoblast cells in a simplified bone niche. Eur Cell Mater. 2012;23:1327. doi:10.22203/eCM.v023a02

18. Prins H-J, Braat AK, Gawlitta D, et al. In vitro induction of alkaline phosphatase levels predicts in vivo bone forming capacity of human bone marrow stromal cells. Stem Cell Res. 2014;12(2):428440. doi:10.1016/j.scr.2013.12.001

19. Cui Q, Wang GJ, Balian G. Steroid-induced adipogenesis in a pluripotential cell line from bone marrow. J Bone Joint Surg Am. 1997;79(7):10541063. doi:10.2106/00004623-199707000-00012

20. Hernigou P, Beaujean F, Lambotte J. Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg Br. 1999;81(2):349355. doi:10.1302/0301-620X.81B2.0810349

21. Sakaguchi M, Tanaka T, Fukushima W, Kubo T, Hirota Y. Impact of oral corticosteroid use for idiopathic osteonecrosis of the femoral head: a nationwide multicenter case-control study in Japan. J Orthop Sci. 2010;15(2):185191. doi:10.1007/s00776-009-1439-3

22. Kubo T, Ueshima K, Saito M, Ishida M, Arai Y, Fujiwara H. Clinical and basic research on steroid-induced osteonecrosis of the femoral head in Japan. J Orthop Sci. 2016;21(4):407413. doi:10.1016/j.jos.2016.03.008

23. Cooper C, Steinbuch M, Stevenson R, Miday R, Watts N. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. Osteoporos Int. 2010;21(4):569577. doi:10.1007/s00198-009-1003-1

24. Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M, Hirota Y. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res. 2010;468(10):27152724. doi:10.1007/s11999-010-1292-x

25. Kang JS, Park S, Song JH, Jung YY, Cho MR, Rhyu KH. Prevalence of osteonecrosis of the femoral head: a nationwide epidemiologic analysis in Korea. J Arthroplasty. 2009;24(8):11781183. doi:10.1016/j.arth.2009.05.022

View original post here:
[Full text] Retrospective Study on Implantation of Autologous-Cultured Osteoblasts | ORR - Dove Medical Press

Recommendation and review posted by Bethany Smith

The Report Titled on Orthopedic Regenerative Medicine Market which provides COVID19 Impact analysis on Market Size (Production, Capacity, Value, Values & Consumption), Regional and Country-Level Market Size, Segmentation Market Growth, Market Share, Competitive Landscape, Sales Analysis, Impact of Domestic and Market Players. Orthopedic Regenerative Medicine Market detailed study of historical and present/future market data. Economic growth, GDP (Gross Domestic Product), and inflation are some of the elements included in this report to offer crystal clear picture of the Orthopedic Regenerative Medicine industry at global level.

Orthopedic Regenerative Medicine Market competitive landscapes provides details by topmost manufactures like (Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.), including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments.

Request for a Sample Report of Orthopedic Regenerative Medicine Market:https://www.coherentmarketinsights.com/insight/request-sample/3566

Market Segmentation & Coverage:

This research report categorizes the Orthopedic Regenerative Medicine to forecast the revenues and analyze the trends in each of the following sub-markets:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Based on Geography, the Orthopedic Regenerative Medicine Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

The Orthopedic Regenerative Medicine Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Apply Promo Code STAYHOME and Get Up to 30% Discount

If you purchase the report this year:

Buy This Complete A Business Report @: https://www.coherentmarketinsights.com/insight/buy-now/3566

The report provides insights on the following pointers:

Market Penetration: Provides comprehensive information on the market offered by the key players

Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets

Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

What is the market size and forecast of the Global Orthopedic Regenerative Medicine Market?

What are the inhibiting factors and impact of COVID-19 shaping the Global Orthopedic Regenerative Medicine Market during the forecast period?

Which are the products/segments/applications/areas to invest in over the forecast period in the Global Orthopedic Regenerative Medicine Market?

What is the competitive strategic window for opportunities in the Global Orthopedic Regenerative Medicine Market?

What are the technology trends and regulatory frameworks in the Global Orthopedic Regenerative Medicine Market?

What are the modes and strategic moves considered suitable for entering the Global Orthopedic Regenerative Medicine Market?

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact Us

Mr. Shah1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027sales@coherentmarketinsights.com

More here:
Orthopedic Regenerative Medicine Market Size to Witness A Lucrative Growth Over 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika...

Recommendation and review posted by Bethany Smith

World Cancer Day: Blood cancer can be managed with treatments such as chemotherapy, radiation therapy

World Cancer Day 2021: This day is observed on February 4. Blood cancer originates in the blood forming tissues when abnormal blood cells start growing out of control, thereby interrupting the functioning of the normal blood cells. The normal blood cells help strengthen the immune system by fighting infection and producing new blood cells. Most blood cancers begin in the bone marrow where blood is produced. The three most common blood cancers are lymphoma, leukaemia and multiple myeloma. The common symptoms include weakness, shortness of breath, minimal injury resulting in fractures, excessive or easy bruising, bleeding gums, recurrent infections and frequent vomiting sensations. Blood cancer can be managed with treatments such as chemotherapy, radiation therapy and stem cell transplant.

Multiple myeloma

Multiple Myeloma develops in the bone marrow and affects plasma cells of the body. Plasma cells are responsible for producing antibodies that attack infections and diseases. When these cells become cancerous, they collect in the bone marrow and weaken the bones, causing pain on movement. They also produce antibodies that are useless and make the body weaker. Some common symptoms for multiple myeloma include low blood count, high calcium levels, kidney problems and spinal cord compression due to weakened bones.

Also read:Cervical Cancer During Pregnancy: Here's All You Need To Know

Lymphoma

Lymphoma affects the lymphatic system, which is responsible for getting rid of toxins in the body. When the immune cells, or lymphocytes, grow out of control, they collect in the lymph nodes, spleen and in other tissues, and organs. The main types are Hodgkins and non-Hodgkin lymphoma. Some common symptoms for lymphomas include painful swelling in the neck, groin, and armpits, fever and drenching sweats, fatigue, unexplained weight loss and shortness of breath.

Leukaemia

Leukaemia is cancer in the bone marrow that gradually spreads to the bloodstream. It is the most common cause of death due to cancer in India. In Leukaemia, the bone marrow produces metamorphosed cells, that outgrow the healthy blood cells gradually. There are multiple forms of leukaemia, but the diagnosis is determined based on speed of symptom development and the type of blood cells that accumulate. Some common symptoms for leukaemia include severe and frequent infections, recurrent nosebleeds, tiny red spots on the skin and excessive sweating and pain in the bones and joints.

While lymphomas and leukaemia affect both children and adults, Myeloma is more prevalent among adults.

Also read:What To Do When A Cancer Patient Tests Positive For COVID-19?

There are several therapies that can be used for treating the different kinds of blood cancer such as:

While there have been developments and advancement in therapies and treatments available for cancer, a significant portion of the future cancer burden can be prevented if we take necessary precautionary measures in the early stages. Better control on tobacco sale and consumption, dietary changes, expansion and equitable distribution of medical facilities, awareness about education programs and risks, prevention, and knowing the benefits of bone marrow donation can go a long way in reducing the burden of blood cancer.

Also read:Alarming Cancer Symptoms Men Should Not Ignore

(Dr Nitin Sood, Director, Hemato Oncology and Stem Cell Transplant Medical and Haemato Oncology, Cancer Institute, Medanta)

Disclaimer: The opinions expressed within this article are the personal opinions of the author. NDTV is not responsible for the accuracy, completeness, suitability, or validity of any information on this article. All information is provided on an as-is basis. The information, facts or opinions appearing in the article do not reflect the views of NDTV and NDTV does not assume any responsibility or liability for the same.

Visit link:
World Cancer Day 2021: Know All About The Different Types Of Blood Cancer From Expert - NDTV Doctor

Recommendation and review posted by Bethany Smith

The Daily Beast

Andrew Harnik/APSenate Majority Leader Chuck Schumer (D-NY) stood alongside high-profile progressives in Congress in front of a podium that said #CANCEL STUDENT DEBT, a favorite slogan of the activist class, to push the Biden administration on a key economic issue.The resolution, which Schumer first introduced last fall with Sen. Elizabeth Warren (D-MA), would cancel $50,000 in student loan debt for each borrower through executive action, a sum that goes far beyond what Biden has already pledged to nix while in office.In an outdoor briefing on Thursday, the Democratic leader said he has already had a receptive response from the White House.We have met with the president, we are pushing the president and his people, and we are very hopeful, Schumer said, sharing that he and Warren met with Biden and administration officials privately for 45 minutes to lay out a proposed executive action.Biden has promised to eliminate $10,000 in federal student loan debt for each student.Asked about the renewed push later in the afternoon, White House press secretary Jen Psaki reiterated Bidens support for his original proposal, suggesting that it was unlikely that anything more would be done through executive orders.On day one, the first day of his administration, he directed the Department of Education to extend the existing pause on student loan payments and interest for millions of Americans with federal student loans, Psaki said. That was a step he took through executive action, but he certainly supports efforts by members in Congress to take additional steps, and he would look forward to signing it.Schumer was joined by Warren and Squad Reps. Ayanna Pressley (D-MA) and Ilhan Omar (D-MN)the original co-sponsors of the companion House resolution from last Decemberas well as other House members pressing the issue.America does not suffer from scarcity, we suffer from greed, Omar said, linking burdensome debt to the differing chances of students who come from wealthy families versus those in middle and working class households.Progressives Cant Find Anyone in Biden's Cabinet to Be Mad AboutYetSchumers desire to publicly present a loan forgiveness alternative to what Biden has offered has been perceived by some on the left as a way to help stave off a possible primary challenge in his native New York. The senior Democrat is up for re-election in 2022 and Rep. Alexandria Ocasio-Cortez (D-NY) is thought to be contemplating a primary challenge for this Senate seat.Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.

See more here:
Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure - Yahoo Finance UK

Recommendation and review posted by Bethany Smith

Excitement took wing in the scientific community in the early 1990s, when the first gene therapy trial showed significant success, only to crash at the end of the decade with a patients tragic death.

Twenty years later, the excitement is back and greater than before. Although safety remains a concern, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cured cancers will follow.

In 2017, the excitement over these therapies returned in spades when the FDA signed off on a cell-therapy drug for the first time, approving the chimeric antigen receptor (CAR) T-cell treatment tisagenlecleucel (Kymriah; Novartis) for patients with B-cell precursor acute lymphoblastic leukemia. At last, scientists had devised a way to reprogram a persons own T cells to attack tumor cells.

Were entering a new frontier, said Scott Gottlieb, MD, then-FDA commissioner, in announcing the groundbreaking approval.

Gottlieb was not exaggerating. The growth in CAR T-cell research is exploding. Although only a handful of cell and gene therapies are on the market, the FDA predicted in 2019 that it will receive more than 200 investigational new drug applications per year for cell and gene therapies, and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year.

We can absolutely cut the number of cancer deaths down so that one day in our lifetimes it can be a rare thing for people to die of cancer, said Patrick Hwu, MD, president and CEO of Moffitt Cancer Center in Florida and among gene therapys pioneers. It still may happen here and there, but itll be kind of like people dying of pneumonia. Its like, He died of pneumonia? Thats kind of weird. I think cancer can be the same way.

Essentially, you can kill any cancer cell that has an antigen that is recognized by the immune cell, Hwu said. The key to curing every single cancer, which is our goal, is to have receptors that can recognize the tumor but dont recognize the normal cells.

Community oncologists will need to be increasingly familiar about the various products, including their immediate and longer-term risks, Bo Wang, MD, and Deepu Madduri, MD, recently wrote in OncologyLive.1 It is key to understand the optimal time for referring these patients to an academic institution, as well as how to manage the requisite post CAR T-cell therapy in the community setting. Madduri is an assistant professor of medicine, hematology and medical oncology, as well as associate director of cellular therapy service, and director of clinical operations with the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai in New York, New York. Wang is a third-year clinical fellow in hematology/oncology at Mount Sinai.

Early referral to academic centers and hospitals equipped to deliver therapies is crucial for patients eligible for therapy. However, as advances continue in the field, community practices may be called upon to administer therapies in their clinic.

The Community Oncology Alliance (COA) envisions a broader role for the settings in which CAR T-cell therapies can be administered. When the Centers for Medicare & Medicaid Services (CMS) was considering coverage for CAR T-cell therapies in 2019, COA officials argued against limiting approvals to hospitals.

It is important to understand that there are state-of-the-art community oncology practices that have significant experience and capabilities in administering highly complex treatments, COA officials wrote in a letter to CMS. For example, stem cell transplants, which are similar in complexity to CAR T therapy, are performed successfully in the community oncology practice setting.2

Broader use of gene therapies depends on several factors, including navigating the logistics of gene therapies, addressing the high costs, and managing toxicities.3

Autologous CAR T-cell therapies involve a manufacturing process that requires coordination between the treating facility and the processing facility. Following leukapheresis, patients may require maintenance therapy to control disease progression during the manufacturing time, which can take 3 to 5 weeks.

In terms of cost, gene and cell therapies can cost from $375,000 to $475,000 per dose and they may face coverage restrictions from payers. Approvals could take weeks to obtain.3,4

Because of cytokine release syndrome and neurotoxicities associated with CAR T-cell therapy, the FDA mandates risk evaluation and mitigation strategy training for centers.

Further, providers may find that real-world experiences with gene therapies are different from those seen in the clinical trial setting, according to Ankit J. Kansagra, MD.

In a presentation at the 2020 American Society of Clinical Oncology Virtual Education Program, Kansagra, an assistant professor of medicine and Eugene P. Frenkel, MD, Scholar in Clinical Medicine at Harold C. Simmons Comprehensive Cancer Center in Dallas, Texas, said that in practice patients may be older and have more aggressive disease, with double- and triple-hit lymphomas.4

Specifically, Kansagra noted that medications such as steroids and/or tocilizumab (Actemra) to prevent or treat cytokine release syndrome or other toxicities were more frequently used in the real-world setting than what had been seen in clinical trials.

As it stands now, only a fraction of eligible patients are receiving CAR T-cell therapies, Kansagra said. Potentially, 9750 patients a year may be eligible for CAR T-cell therapies in approved and upcoming hematologic indications. From 2016 to 2019, a total of 2058 patients received CAR T-cell infusion.4

Next steps for transplanting these novel therapies to clinical practice will require changes in key areas, Kansagra said, such as supply chain management, patient support, and financial systems (Figure).4

Figure. Next Steps for Effective Delivery of Gene and Cell Therapies4

Meanwhile, multiple myeloma experts advise providers to be ready for change. As commercially available myeloma CAR T-cell therapies are approved, it will be even more important for community oncologists to better understand these therapies so they can offer them to their patients, Wang and Madduri wrote.1

Cell therapy involves cultivating or modifying immune cells outside the body before injecting them into the patient. Cells may be autologous (self-provided) or allogeneic (donor-provided); they include hematopoietic stem cells and adult and embryonic stem cells. Gene therapy modifies or manipulates cell expression. There is considerable overlap between the 2 disciplines.

Juliette Hordeaux, PhD, senior director of translational research for the University of Pennsylvanias gene therapy program, is cautious about the FDAs predictions, saying shed be thrilled with 5 cell and/or gene therapy approvals annually.

For monogenic diseases, there are only a certain number of mutations, and then well plateau until we reach a stage where we can go after more common diseases, Hordeaux said.

Safety has been the main brake around adeno-associated virus vector [AAV] gene therapy, added Hordeaux, whose hospitals program has the institutional memory of both Jesse Gelsingers tragic death during a 1999 gene therapy trial as well as breakthroughs by 2015 Giants of Cancer Care winner in immuno-oncology Carl H. June, MD, and others in CAR T-cell therapy. Sometimes there are unexpected toxicity [events] in trials.I think figuring out ways to make gene therapy safer is going to be the next goal for the field before we can even envision many more drugs approved.

In total, 3 CAR T-cell therapies are now on the market, all targeting the CD19 antigen. Tisagenlecleucel was the first. Gilead Sciences received approval in October 2017 for axicabtagene ciloleucel (axi-cel; Yescarta), a CAR T-cell therapy for adults with large B-cell non-Hodgkin lymphoma. Kite Pharma, a subsidiary of Gilead, received an accelerated approval in July 2020 for brexucabtagene autoleucel (Tecartus) for adults with relapsed/ refractory mantle cell lymphoma.

Another CD19-directed therapy under FDA review for relapsed/refractory large B-cell lymphoma, is lisocabtagene maraleucel (liso-cel; JCAR017; Bristol Myers Squibb). Idecabtagene vicleucel (ide-cel; bb2121; Bristol Myers Squibb) is under priority FDA review, with a decision expected by March 31, 2021. The biologics license application for ide-cel seeks approval for the B-cell maturation antigendirected CAR therapy to treat adult patients with multiple myeloma who have received at least 3 prior therapies.5

The number of clinical trials evaluating CAR T-cell therapies has risen sharply since 2015, when investigators counted a total of 78 studies registered on the ClinicalTrials. gov website. In June 2020, the site listed 671 trials, including 357 registered in China, 256 in the United States, and 58 in other countries.6 Natural killer (NK) cells are the research focus of Dean A. Lee, MD, PhD, a physician in the Division of Hematology and Oncology at Nationwide Childrens Hospital in Columbus, Ohio. He developed a method for consistent, robust expansion of highly active clinical-grade NK cells that enables repeated delivery of large cell doses for improved efficacy. This finding led to several first-in-human clinical trials evaluating adoptive immunotherapy with expanded NK cells under an FDA investigational new drug application. Lee is developing both genetic and nongenetic methods to improve tumor targeting and tissue homing of NK cells. His efforts are geared toward pediatric sarcomas.

The biggest emphasis over the past 20 to 25 years has been cell therapy for cancer, talking about trying to transfer a specific part of the immune system for cells, said Lee, who is also director of the Cellular Therapy and Cancer Immunology Program at Nationwide Childrens Hospital, at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital, and at the Richard J. Solove Research Institute.

However, Lee said, NKs have wider potential. This is kind of a natural swing back. Now that we know we can grow them, we can reengineer them against infectious disease targets and use them in that [space], he said.

Lee is part of a coronavirus disease 2019 (COVID-19) clinical trial, partnering with Kiadis, for off-the-shelf K-NK cells using Kiadis proprietary platforms. Such treatment would be a postexposure preemptive therapy for treating COVID-19. Lee said the pivot toward treating COVID19 with cell therapy was because some of the very early reports on immune responses to coronavirus, both original [SARS-CoV-2] and the new [mutation], seem to implicate that those who did poorly [overall] had poorly functioning NK cells.

The revolutionary gene editing tool CRISPR is making its initial impact in clinical trials outside the cancer area. Its developers, Jennifer Doudna, PhD, and Emmanuelle Charpentier, PhD, won the Nobel Prize in Chemistry 2020.

For patients with sickle cell disease (SCD), CRISPR was used to reengineer bone marrow cells to produce fetal hemoglobin, with the hope that the protein would turn deformed red blood cells into healthy ones. National Public Radio (NPR) did a story on one patient who, so far, thanks to CRISPR, has been liberated from the attacks of SCD that typically have sent her to the hospital, as well from the need for blood transfusions.7

Its a miracle, you know? the patient, Victoria Gray of Forest, Mississippi, told NPR.

She was among 10 patients with SCD or transfusion-dependent beta-thalassemia treated with promising results, as reported by the New England Journal of Medicine.8

Stephen Gottschalk, MD, chair of the department of bone marrow transplantation and cellular therapy at St Jude Childrens Research Hospital, said, Theres a lot of activity to really explore these therapies with diseases that are much more common than cancer.

Animal models use T cells to reverse cardiac fibrosis, for instance, Gottschalk said. Using T cells to reverse pathologies associated with senescence, such as conditions associated with inflammatory clots, are also being studied.

CAR T, I think, will become part of the standard of care, Gottschalk said. The question is how to best get that accomplished. To address the tribulations of some autologous products, a lot of groups are working with off-the-shelf products to get around some of the manufacturing bottlenecks. I believe those issues will be solved in the long run.

Read the rest here:
Harnessing the Potential of Cell and Gene Therapy - OncLive

Recommendation and review posted by Bethany Smith

In pursuit of life everlasting, some turn to God. Others turn to science. Or rather, something science-ish.

If you've ever hoped to be cryogenically frozen, you might come across a legal hurdle: while human cryonics is legal in several countries, you have to be dead before going into the cryonics tank. Otherwise, freezing someone alive is tantamount to killing. So, as it is, you can only get your dead body or head frozenand when thawed, you'd still be dead.

This doesn't deter some people, who simply hope to be cryopreserved until the day comes that humanity masters the art of resurrection, so scientists can re-animate them and cure their ailments. Or upload their consciousness into the cloud. Whichever comes first.

But for those of you who would prefer to go on ice before the immutability of brain death takes hold, there may be a legal loophole to help. According to The Telegraph, one company hopes to avoid that legal issue entirely by building a cryonics lab in a country where human euthanasia is legal.

If Russian cryonics company KrioRus manages to fund it, they plan to buy a bunker in Switzerland and convert it to a cryopreservation lab. People with one foot in the grave could fly in from around the world and be placed in a cryopreservation tank, awaiting the day when their otherwise-fatal disease is cured, and their body is revived to go on living. (Alternatively, they can consider being awoken when we can upload our consciousness to computers, and we won't need our flesh-prisons. I hear that day is near.)

Cryonics is the idea that you can use extremely low temperatures to preserve humans and animals through cryogenic freezing. It's basically like the premise of Futurama, but without the egg timer. However, the procedure is controversial, and the only humans that have been revived after cryogenic freezing are living embryos. The process would probably kill an adult. In Switzerland, though, that could potentially be passed off as "euthanasia."

However, cryonics is unregulated, controversial and unproven to work. Technically, though, cryogenic freezing of non-humans can be used for less science-fictiony endeavors and is not synonymous with cryonics.

According to its website, KrioRus is the first Eurasian company to preserve people and pets, hosting 50 human bodies or heads and 20 animals in tanks in Moscow and St. Petersburg. They have so far only worked with people who have been declared legally dead (and not Walt Disney ). Freezing your body is $36,000, and a head will set you back $12,000.

There's no guarantee that the Swiss pursuit of pre-mortem freezing will go anywhere, let alone conquer mortality. Perhaps the field of cryonics is just trading one eternal, icy embrace for another.

Go here to read the rest:
Cryonics company hopes to use legal loophole to freeze ...

Recommendation and review posted by Bethany Smith

At the age of 18, Emil Kendziorra had a life plan.

First, he was going to become a doctor. Then he was going to make heaps of money. Then he was going to use that money to start a longevity business helping people (and himself) live a much longer life.

One of the things that motivates me is the fear of death, Kendziorra tells Sifted. I dont want to die.

Advertisement

The first bit of the plan went exactly as imagined.

He became a doctor. Then he made a lot of money in tech founding companies, including software business Solid Media, a restaurant review site Onfeedback and then doctor-on-demand-network Medlanes (which was acquired last month).

But there was a snag. When researching what was happening in the longevity sector to start his new business, he felt pessimistic that the science would go far enough in his lifetime so he and others really could live forever.

One of the things that motivates me is fear of death

This was a tough moment for the 35-year-old, who had to rethink the next stage of his life plans. If you look at how far science has gotten, it is unlikely that a solution will be found within my lifetime, he says.

This prompted him to take a new path, getting into an even more esoteric field: the cryogenic freezing of people on their deathbed.

He now has a business called Tomorrow Biostasis that in exchange for an insurance payment of 30100 per month will cryopreserve users bodies from -130 to -196 degrees celsius with the idea that they will one day be resurrected.

Its part of a growing trend of companies getting into this field. But why is he freezing people? How does it work? And does it even work?

If there is a fair bit of scepticism out there about the whole science of longevity, or living forever, there is even more so about cryonics.

Cryonics is probably best known for showing up in films like 2001: A Space Odyssey, Vanilla Sky or the television series Futurama.

The technology was also recently featured in a documentary on Netflix in which the parents of a terminally ill two-year-old decided to cryogenically preserve her brain.

The idea of inducing metabolic stasis in humans using cryogenic temperatures was proposed in the 1960s as a way of preventing structural decay of the brain, following the terminal failure of the body.

Indefinitely preserving the brains physical state was though to leave open the possibility of resuscitating consciousness: in other words, by restoring function to the brain using one of several theorised but as of yet undeveloped techniques such as digital reconstruction or nanobot cellular repair.

The idea of the technology has long been to freeze the human body shortly after pronounced legally dead, replace the blood with a solution designed to preserve the organs and then adding a so-called cryoprotectant solution that freezes cells without causing crystal formation. Then the body is kept in cold storage until the technology has developed enough to successfully revive the body.

The trouble is that this might, of course, never actually work something Kendziorra readily admits. But he says that there are few scientists who say that this will definitely never be possible just different ideas about how likely it is to ever work.

From scientists in the community, that I would all say are good scientists, the range is from, 2%, to 90% [likelihood that it will work], he says.

But just because it is described as science fiction doesnt mean that one should give up, according to Kendziorra.

The first heart transplant was done in 1967 and if you had asked doctors before that, if it was possible, their answer would probably have been no, you are insane.But that is not reason enough not to try making it happen.

In late 2018, Kendziorra set up a company called Tomorrow Biostasis where people all over Europe are able to sign up for cryogenically freezing and storing when they die.

Working with big insurance companies, users pay a monthly fee for the right to be frozen. Similar to life insurance, it only is a guarantee as long as you are under the age of 60 or 70 depending on the plan.

So far the startup says it is on the trajectory of having 500 customers signed up in the next few months.

But even the freezing is hard.

One thing that is very important, logistically speaking, is if someone dies, you need to be there quickly to start the cooldown process, otherwise the cell damage starts to happen, Kendziorra says.

Alcor, one of the leading US companies when it comes to cryopreservation, believes that the process needs to start within minutes of death, however, this rarely happens due to delays at the hospital where the patient died.

Others would argue that severe cell damage caused by a body left dead for several hours, cannot be reversed, not even with the best medical nanorobots of the future.

Kendziorra is a bit more optimistic and Tomorrow Biostasis picks up people across Europe.

We have a medical response team that has a specialised ambulance vehicle, which is basically a mobile operating room, that is dispatched to pick up the patient, he says.

When the patient is ready for long-term storing, Tomorrow Biostasis uses non-profit organisations set up for this work.

According to Kendziorra, 100k is set aside for each patient. That money is then invested with the idea of 23% return of investment per year 2% for inflation and 1% to pay for the storage of the body.

The idea is that over time, even if it takes 50 or 100 years, you only use the interest and always keep the principle that you had in the beginning. Then you have this money available to pay for revival, Kendziorra says.

And some of that money would also be put aside as pocket money after one is revived. Whether money even exists and how one would fit into society a century from now are two different questions.

Apart from Tomorrow Biostasis, there arent a lot of cryonic startups in Europe. According to Kendziorra, the Swiss-Russian company Kriorus had some internal problems that had a negative effect on the reputation of the company.

One thing that is very important, logistically speaking, is if someone dies, you need to be there quick to start the cooldown process, otherwise the cell damage starts to happen

Kendziorra believes that trust and stability are key for a cryonics company. So far Tomorrow Biostasis has only raised an undisclosed amount from angel investors in Berlin and Silicon Valley but is planning for a larger funding round for 2021.

If you want more companies to choose from, youd better turn to the US.

Based in Arizona and by being around for 40 years, Alcor has perhaps helped the reputation of the technology, particularly in Silicon Valley.

To put yourself on ice is something that both PayPal founder Peter Thiel and computer scientist Ray Kurzweil have signed up to. In 2017, the AI-run hedge fund Numerai allowed employees cryonic body preservation as a benefit.

To be afraid of dying is not the only motivator for people that sign up for cryopreservation, according to Kendziorra.

Apart from not liking the idea of non-existence, I believe that people, who want this, think positively about life and therefore want it for longer. Another common motivation is also a curiosity about how life will look in the future. I think its always a combination of these three motivations. And I would say I subscribe to all of them, he says.

Mimi Billing is Sifteds Nordic correspondent. She also covers healthtech, and tweets from @MimiBilling

View original post here:
Putting dead heads on ice until the technology catches up - Sifted

Recommendation and review posted by Bethany Smith

With her sun-kissed hair and flawless golden skin, it's easy to forget that Heidi Klum is in her mid 40s. Genetics certainly help. But so do Heidi Klum's favourite skincare products by Glossier and Drunk Elephant, plus a reminder of home courtesy of German beauty brand The Cream by Augustinus Bader.

In a rare selfie, Klum showed off the Perfectil Hair Skin And Nails Vitamins she takes daily, alongside this smorgasbord of beauty products, which proves the supermodel takes her skincare seriously.

Here are some of her favourite products:

More from womanandhome:

Drunk Elephant T.L.C. Framboos Glycolic Resurfacing Night Serum

This night serum contains a hefty dose of glycol acid to exfoliate built-up dead skin cells and resurface dull, uneven skin. Expect brighter, smoother skin when you wake.

Drunk Elephant T.L.C. Sukari Babyfacial 25% AHA + 2% BHA Mask

If you like to feel a product working, you'll positive love this mask. Like an AHA/BHA facial in a bottle, it resurfaces skin to reveal greater clarity and improved skin tone.

Drunk Elephant C-Firma Day Serum

This vitamin C day serum is packed with antioxidants to protect skin from urban aggressors.

Glossier Solution

A liquid exfoliator that you apply a bit like toner, it buffs away dead dulling skin with a single swipe.

Mario Badescu Drying Lotion

We know, we know, even supermodels get spots. This cult zit lotion contains salicylic acid, sulfur, and zinc oxide to dry up blemishes - fast.

Augustinus Bader The Rich Cream

The brainchild of a stem cell scientist no less, this overnight treatment uses amino acids and vitamins to re-energise cells to repair damage more effectively.

Original post:
Heidi Klum loves to pamper her skin with goodies from Drunk Elephant and Glossier - Woman & Home

Recommendation and review posted by Bethany Smith

CHICAGO, Feb. 2, 2021 /PRNewswire/ -- Paragon Biosciences, a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence, today announced the launch of CiRC Biosciences, a cell therapy company developing treatments for serious diseases with high, unmet needs with an initial focus on the eye.

"The addition of CiRC Biosciences to our portfolio builds upon our cell and gene therapy platform, an area that has tremendous potential to address serious genetic diseases," said Jeff Aronin, founder, chairman and chief executive officer of Paragon Biosciences. "CiRC Biosciences gives us the science to target retinal diseases that could lead to vision restoration with numerous other applications in the years ahead."

CiRC Biosciences is currently advancing pre-clinical development of chemically induced retinal cells for vision restoration in Geographic Atrophy Age-Related Macular Degeneration (Dry AMD), which is the most common cause of irreversible vision loss over the age of 65, and advanced Retinitis Pigmentosa (RP), a genetic disorder that causes tunnel vision and eventual blindness. There are no U.S. Food & Drug Administration (FDA) approved treatments to restore vision loss in Dry AMD or RP.

The company's novel mechanism of action is designed for direct chemical conversion of fibroblasts into other cell types using a cocktail of small molecules in an 11-day chemical conversion process. Pre-clinical studies have shown efficacy in blind mice that demonstrated vision restoration. CiRC Biosciences has provisional patent applications to protect its platform.

"Our technology transforms ordinary skin cells into specialized retinal cells using a cocktail of small molecules," said Sai Chavala, M.D., co-founder and chief scientific officer of CiRC Biosciences. "This process is potentially safer, quicker, more cost effective and easier to manufacturer than using traditional stem cells. Working with Paragon Biosciences to build and advance CiRC Biosciences provides us the opportunity to efficiently progress this technology through research and development stages.

CiRC Biosciences first reported its discovery in the highly respected scientific journal Nature (April 15, 2020). A recently published New England Journal of Medicine article (Nov. 5, 2020)discussed CiRC's technology of using chemically induced cells to restore retinal function. The article concluded, "The new and emerging strategies for the rescue, regeneration, and replacement of photoreceptors suggest a bright future in the fight to preserve and restore vision in blinding eye diseases."

The abstract in Nature is available here: https://www.nature.com/articles/s41586-020-2201-4

Access to the NEJM article is available here: https://www.nejm.org/doi/full/10.1056/NEJMcibr2027602

About CiRC Biosciences CiRC Biosciences is a privately held cell therapy company dedicated to developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Currently it is pre-clinical phase for Geographic Atrophy Age-Related Macular Degeneration (Dry AMD) and advanced Retinitis Pigmentosa (RP). CiRC Biosciences is a portfolio company of Paragon Biosciences. Visit our website: https://circbiosciences.com/.

About Paragon Biosciences Paragon is a life science innovator that creates, invests in and builds life science companies in biopharmaceuticals, cell and gene therapy and synthetic biology utilizing artificial intelligence. The company's current portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, Skyline Biosciences, and a consistent flow of incubating companies created and supported by the replicable Paragon Innovation Capital model. Paragon stands at the intersection of human need, life science, and company creation. For more information, please visit https://paragonbiosci.com/.

Media Contact:

Evelyn M. O'Connor Paragon Biosciences 312-847-1335 [emailprotected]

SOURCE Paragon Biosciences

Home

Read the rest here:
Paragon Biosciences Launches CiRC Biosciences to Expand Cell and Gene Therapy Platform - PRNewswire

Recommendation and review posted by Bethany Smith

Yahoo Life is committed to finding you the best products at the best prices. We may receive a share from purchases made via links on this page. Pricing and availability are subject to change.

As we continue to stare down several more weeks of winter (or more, pending what Punxsutawney Phil determines in a few days), its more important now than ever to take care of our winter-worn skin and hair. And under quarantine where, lets face it, a lot of us have been skipping certain steps in our self-care routines, having the kind of products that can not only protect but help restore some neglected areas is all the more important.

You (and your skin) are in luck: M3 Naturals has a wide range of personal care products perfect to help you feel and look better with every scrub, lather and shampoo. And today only, you can get up to 60 percent off these Amazon best-sellers.

Whether youre looking to battle wrinkles, clear up your skin, or just treat yourself in the shower, make sure to grab these before the deal ends its only for today.

With over 13,000 five-star reviews, this salt scrub boasts a plethora of good-for-your-skin benefits, from detoxifying and clearing to anti-aging, thanks to the potent blend of collagen and stem cells in the formula. Plus, natural ingredients like lychee fruit and sweet almond oil make it great for cleansing. Even better? Its made in the USA.

Shoppers cant get enough of the scrub, with one reviewer raving: Worth every penny! SO HAPPY I BOUGHT! adding, I love the relaxing feeling I get Scrubbing in the shower I instantly feel better.. all dead skin gone and left with super soft amazing looking skin!

Shop it: M3 Himalayan Salt Scrub, $14 (was $33), amazon.com

Battling crows feet and fine lines around your eyes? Just a few dabs once or twice a day can help reduce wrinkles, puffiness, or dark circles. With a combination of hyaluronic acid, stem calls and collagen, the M3 Naturals Eye Cream is designed to deliver results. Plus, it has nearly 2,400 five-star reviews!

Story continues

I have had bags and wrinkles under my eyes my entire life, one reviewer noted, I figured I would give this a try because of the reviews and such a difference! It was hard to capture the dark circles but those have lightened soooo much too. I am so excited and plan to buy another when I run out!

Shop it: M3 Eye Cream, $23 (was $29), amazon.com

Hair loss can affect both men and women, and while its certainly less stigmatized (thanks to Charlize Theron in Max Max for showing us that a cropped look can be mega stylish), we still want to be in control over our hairstyle, instead of letting our follicles decide for us. For those of us who want to give our scalp a push in the right direction, look no further than the M3 Hair Growth Shampoo. Its combination of collagen, biotin and argan oil help encourage thicker, healthier hair with a DHT blocker formula.

Hundreds of shoppers swear by this shampoo, with one sharing: My hair is very thin and I am only 39 years old...I have been using this only for a week and can already see a difference in the growth of my hair and also the thickness. It leaves your hair feeling so clean literally all day not like when I use other shampoo products. It smells pretty good actually and it has not left my hair greasy or anything. I also noticed I no longer have dandruff. I love this stuff.

Shop it: M3 Hair Growth Shampoo, $14 (was $18), amazon.com

This made-in-the-USA retinol is designed to be used on both your face and neck, and thanks to a potent infusion of collagen and stem cells, can tackle both fine lines and deep wrinkles. Its not just a wrinkle buster, either: The formula hydrates, brightens, and firms.

Shoppers agree, with one five-star reviewer happily reporting: This moisturizer is REALLY good! First, I love that it comes in a jar where you simply push down on the top and the lotion comes out. You get to control how much of the product actually comes out. (No more putting your fingers into a jar of lotion over and over.) Second, the lotion is thick, but not too thick. It is just the right consistency for a good facial moisturizer. It doesn't have a smell, and it doesn't take much product to cover your entire face and neck. I have only been using it for about a week, but I already completely love it!

Shop it: Retinol Moisturizer, $14 (was $18), amazon.com

For those of us who live and die by the drip of our Nespresso, were prone to believe coffee is nothing short of a miracle bean. But even the most devoted drinker will be blown away by how effective this Arabica Coffee Scrub is at cleansing and revitalizing skin. Not only does this scrub help promote smoother, healthier skin, but the subtle scent will help give you an extra bit of pep in your step. Looks like your favorite bean is just as good on your skin as it is in your cup.

Over 1,600 five-star shoppers found this scrub irresistible, with one reviewer who bought it as a gift admitting: This coffee scrub is fantastic! I bought it for my husband but I ended up using it, too! It really removes dead skin and doesn't leave your skin dry like other scrubs do. It is gentle enough for sensitive skin but works really well on rough patches of skin, too. It rinses clean and smells AMAZING.

Shop it: Arabica Coffee Scrub, $23 (was $29), amazon.com

The reviews quoted above reflect the most recent versions at the time of publication.

Read More from Yahoo Lifestyle:

Follow us on Instagram, Facebook, Twitter, and Pinterest for nonstop inspiration delivered fresh to your feed, every day

Want daily pop culture news delivered to your inbox? Sign up here for Yahoo Entertainment & Lifestyle's newsletter.

Continue reading here:
Amazon just slashed up to 60 percent off this top-rated skincare brand but only for today - Yahoo Sports

Recommendation and review posted by Bethany Smith

According to Persistence Market Researchs new report,globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceedUS$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/22303

Company Profiles

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/22303

Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period.

Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

Access Full Report @https://www.persistencemarketresearch.com/checkout/22303

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Explore Extensive Coverage of PMR`s

Life Sciences & Transformational HealthLandscape

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor, New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

https://murphyshockeylaw.net/

Read more:
The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law

Recommendation and review posted by Bethany Smith

Fatigue is one of the most common adverse events of systemic therapy in patients with metastatic renal cell carcinoma (RCC). The aim of multicenter randomized phase 2 study was to determine the efficacy and safety of testosterone in patients with fatigue developed during targeted therapy.

Male patients with metastatic clear-cell RCC, normal prostate-specific antigen level, low testosterone level, and no evidence of hypothyroidism receiving first-line sunitinib or pazopanib with fatigue were randomly assigned (1:1) to either testosterone undecanoate (1000mg) and targeted therapy or targeted therapy alone. The primary endpoint was the mean change of fatigue from baseline to 28 days according to the Functional Assessment of Chronic Illness Therapy-Fatigue scale. Secondary endpoints were safety, Functional Assessment of Cancer Therapy-Kidney Symptom Index 19, testosterone serum concentrations, red blood cell count, and hemoglobin level.

Sixty patients were assigned to receive testosterone and targeted therapy (N=30) or targeted therapy alone (N=30). As of the data cutoff on December 30, 2019, median follow-up was 18.2 months. The study achieved its primary endpoint based on the significant differences at day 28 favoring testosterone over targeted therapy alone regarding the decreased level of fatigue (difference between groups, 22.5 points; 95% confidence interval, 18.4-26.6; P=0.012). Significant changes in scores demonstrating the enhanced quality of life with testosterone compared with targeted therapy were also observed for Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 disease-related symptoms (P=0.01). There were nonsignificant differences in red blood cell count and hemoglobin level between the 2 groups (all P>0.05).

Male patients with metastatic RCC and hypogonadism receiving testosterone had less fatigue and better symptom control during targeted therapy.

American journal of clinical oncology. 2021 Jan 27 [Epub ahead of print]

Ilya Tsimafeyeu, Yulia Tishova, Ruslan Zukov, Pavel Borisov, Anastasia Bondarenko, Kristina Zakurdaeva

Kidney Cancer Research Bureau Institute of Oncology, Hadassah Medical Moscow RUDN University I.M. Sechenov First Moscow State Medical University RakFond, Moscow V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk City Clinical Oncology Center, St. Petersburg, Russia.

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33512910

Originally posted here:
Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday

Recommendation and review posted by Bethany Smith

If you find yourself managing busy family life, social life, and career, its common to feel tired and achy sometimes. But do ever wonder if youre achiness and fatigue maybe something more? Are they symptoms of a stressful life, or could they be tied to an underlying condition like an autoimmune disease?

Dr.Redd, a Chiropractic Physician with a Masters in Human Nutrition from RedRiver Health and Wellness is addressing why many people with low thyroid and auto-immunityissues still have their symptoms after being on medication and seeing many specialists. Symptoms of autoimmune disease may be severe in some people and mild in others, but there is a way to get help as one lifelong athlete found.

Nicole, an avid fitness fan and now a recovered patient of RedRiver Health, explained how she feels after seeing Dr.Redd. RedRiver works to make patient satisfaction a top priority and every chiropractic physician and administrative team member works hard to ensure that each patient receives attention and individualized care.

Suffering from chronic symptoms that affect your ability to live your life can be frustrating. Many people visit multiple doctors and specialists and still cant find good answers about what is causing symptoms. People often brush symptoms off as just being the result of a busy and active lifestyle, or the result of stress from kids, work, and life in general. But when they start to get in the way of your ability to live your life its time to figure out exactly whats causing these symptomsa proper diagnosis is critical to find the right treatment.

RedRiver start with extensive testing that delves deeper than most lab panels, then add testing for everything from food sensitivity or intolerance to parasites, hormone imbalances, and adrenal function. They work to understand exactly what is happening inside your body so we can effectively eliminate the issues you are experiencing today while avoiding future flare-ups or a return of symptoms.

RedRiver Health and Wellness has offices in Springville, St. George, Logan, and South Jordan.

For more information, visitRedRiver Health or call (866) 36-RIVER for a free consultation or download a free guide on their website.

This story contains sponsored content.

Read more from the original source:
Lifelong athlete recovers from a hidden health condition that plagued her for years - ABC 4

Recommendation and review posted by Bethany Smith

USADA announced today that Abu Azaitar, of Rabat, Morocco, has accepted a seven-month sanction for a violation of the UFCAnti-Doping Policy.

Azaitar, 34, tested positive for tamoxifen and/or tamoxifen metabolite 3-hydroxy-4-methoxy-tamoxifen as the result of urine samples collected on August 25, 2020, September 4, 2020, September 9, 2020 and September 17, 2020. Tamoxifen is a Specified Substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy and UFC Prohibited List.

After being notified of his positive test, Azaitar provided evidence (including medical records), that he was prescribed tamoxifen by a physician to treat symptoms. Tamoxifen is a selective estrogen receptor modulator used therapeutically to treat certain types of cancer in females and also prescribed off-label for males with various other conditions. Although the substance was taken at the direction of a physician, Azaitar lacked a valid Therapeutic Use Exemption (TUE) and his subsequent application for a retroactive TUE was denied due to lack of sufficient medical justification. Under the applicable rules, Azaitar was eligible for a reduction to the period of ineligibility based on the specific circumstances of his case and for his Full and Complete Cooperation.

Azaitars seven-month period of ineligibility began on August 25, 2020, the date his first positive sample was collected.

Read Full Statement

View post:
Statement on Abu Azaitar | UFC - The Official Website of the Ultimate Fighting Championship

Recommendation and review posted by Bethany Smith

Hi, everyone. I'm Dr Kenny Lin. I am a family physician at Georgetown University Medical Center, and I blog at Common Sense Family Doctor.

Kenneth W. Lin, MD, MPH

2020 was a very tough year for primary care clinicians, even when we weren't regularly treating patients with COVID-19. Last spring, the number of preventive services provided at community health centers well-child visits, Pap smears, A1c tests for patients with diabetes, and screening mammograms fell by one half to two thirds compared with the previous year and had not returned to their usual levels by the end of the summer. Although in some cases telehealth can replace in-person visits, a retrospective analysis posted online ahead of print by the American Academy of Family Physicians' Robert Graham Center suggested that two thirds of typical primary care visits require at least one in-person service, such as an immunization or blood draw.

Pandemic-related declines in well-child visits and adult physical examinations not only had negative financial effects on primary care practices, but also raised fears that delayed cancer diagnoses would lead to thousands of preventable deaths in children (O'Neill A and colleagues; Ding Y and colleagues) and in adults (Sharpless NE; Maringe C and colleagues). As a result, even though daily death and hospitalization rates from COVID-19 are exceeding the peaks from last spring and summer, hospitals and medical practices have been strongly encouraging patients not to defer routine care.

Medical offices are generally safer for patients now than they were during the first few months of the pandemic, when infectious disease protocols were not well established, and in many places surgical masks and other PPE were in short supply. But we do patients a disservice by pretending that primary care can or should return to "business as usual." Preventive services, by definition, are offered to persons without symptoms of the diseases we are trying to prevent, and false-positive test results can lead to harmful diagnostic cascades. For example, one study found that nearly 1 in 5 seniors who underwent a Medicare annual wellness visit in 2014 received at least one nonrecommended test (eg, electrocardiography, urinalysis, thyroid-stimulating hormone), and many of these "low value" tests led to further tests that required additional in-person encounters.

Even for recommended screenings, overall benefits may only exceed harms by a small margin (Ropeik D; Carr T). Compared with management of acute symptoms or chronic conditions, cancer screening does not help most patients; the best evidence indicates that one needs to screen approximately 1000 patients to avoid one death from breast, colorectal, or prostate cancer.

Last summer, current and former members of the Canadian Task Force on Preventive Health Care argued that the increased infection risk associated with an in-person healthcare visit during the pandemic should cause us to consider extending recommended screening intervals and permanently abandon the evidence-free tradition of performing annual or periodic physical examinations on adults without a specific indication. I wholeheartedly agree!

The development of effective coronavirus vaccines has raised hopes that disruptions to primary care will only persist until enough people have been immunized to make it safe to fill up our waiting rooms again. That prediction may turn out to be true, but it would be a shame to miss this once-in-a-lifetime opportunity to reassess the value of routine medical services.

Sorenson and colleagues have suggested that health professional organizations develop "do not restart" lists for their members on pandemic-deferred services that are wasteful or likely to do more harm than good; the American Board of Internal Medicine's Choosing Wisely campaign is a good place to begin. I propose that family medicine's "do not restart" list include not only outdated tests but office processes, too, including the aforementioned waiting room. As is routine in many restaurants and hair salons, patients could wait outside or in their vehicles and receive a text message when it's time for them to be seen, limiting exposure to other potentially ill persons and allowing the practice to use the no-longer-needed waiting space for another purpose.

Kenny Lin, MD, MPH, teaches family medicine, preventive medicine, and health policy at Georgetown University School of Medicine. He is deputy editor of the journalAmerican Family Physician.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See the article here:
Ditch the Waiting Room (and Other Post-COVID Ideas) - Medscape

Recommendation and review posted by Bethany Smith

Every year, the month of January is celebrated as Thyroid Awareness Month to raise awareness regarding the various health problems related to the thyroid gland. The thyroid is a small, butterfly-shaped gland located at the base of the neck and plays a major role in the metabolism, growth, and development of the human body. It also helps in regulating several body functions by releasing hormones into the bloodstream.

If the thyroid gland doesnt function properly, you may develop several diseases, including hyperthyroidism, hypothyroidism, Hashimotos disease, Graves disease, goiter, and thyroid cancer.

Thyroid awareness month seeks to raise awareness regarding these diseases, their causes, symptoms, treatment, and prevention.

Symptoms of Hypothyroidism

Symptoms of Hyperthyroidism

Stand in front of a mirror, tilt back your head, and take a sip of water

Observe the area below Adams apple for signs of bulging

Repeat the process a few times and note down the observations

If you see excessive bulging, nodules, or enlarged glands, contact your physician immediately

The only way to be sure, however, is to perform a blood test that measures your thyroid hormone levels. Usually, a physician would recommend a TSH (Thyroid Stimulating Hormone) test. Depending on the amount of hormone present in your system, the physician can then zero in on the type of thyroid disorder that you may be suffering from and prescribe appropriate treatment accordingly.

It is much more difficult to diagnose thyroid-related disorders in senior citizens because many of the symptoms associated with a malfunctioning thyroid gland overlap with the symptoms of aging. Symptoms like loss of memory, weight gain, and constipation are a few examples.

January is thyroid awareness month: All you need to know about thyroid disorders

Read more| Tax benefits for investing in national pension system: Here's all you need to know

Read more from the original source:
January is thyroid awareness month: All you need to know about thyroid disorders - India Today

Recommendation and review posted by Bethany Smith

Since February is American Heart Health month, what better time to raise awareness of heart disease and stroke, especially among women. Did you know that heart disease is the No. 1 cause of death for women in the United States? More women than men die of heart disease, but many women are unaware of the danger theyre in.

Heart disease is a term that covers several types of diseases of the heart, blood, arteries, and veins. Having heart disease can often result in heart failure, heart attack, stroke, or peripheral artery disease. The risks for developing heart disease range from age, gender, family history, diet, blood pressure, level of cholesterol, diabetes, obesity, and stress.

It doesnt take much to improve your heart health for both men and women. In fact, heart disease is about 80 percent preventable when you make the right choices. Ready to make over your heart? Lets get started.

There are a couple of things that always need to be stressed. First, avoid cigarette smoking and secondhand smoke. The reasons are clear: Smoking contributes to the buildup of fatty substances in the arteries, increases blood pressure, and lowers good (HDL) cholesterol. Plus, a double whammy for the heart, smokers also tend to have more difficulty exercising.

You dont have to quit alone. Smoking cessation classes are offered at Bingham Memorial Hospital. For more information, please call (208) 785-3820.

Physical activity is so powerful. If you can do nothing else, move every day. People who are active are better at controlling their weight, keeping blood pressure low, and managing cholesterol levels.

You dont need to huff and puff to reap the benefits a daily 30-minute brisk walk (or three 10-minute walks) is a good start.

A healthy diet is essential to a healthy heart. Start by avoiding processed foods and loading up on fruits and vegetables. Having a colorful plate leads to heart-healthy choices. Favor vegetables over fruit preferably.

One of the keys to a healthier ticker is managing stress.

Stressful situations can start a number of chain reactions. Your body releases adrenaline, a hormone that temporarily causes your breathing and heart rate to speed up, and if youre under constant stress, this can keep happening on and off.

While researchers are still trying to understand the exact link, they do know that stress raises blood pressure levels. And for some people, it might invite unhealthy coping mechanisms, like smoking or alcohol.

So what can you do to chill out? Its easy. Youll feel better with just 20 minutes of daily laughter, meditation, yoga, or even just deep breathing.

When we dont get enough sleep, we see increases in the stress hormone cortisol and blood pressure levels. Constantly elevated cortisol and blood pressure damages the lining of the blood vessels of the heart. Try to aim for seven to eight hours of shuteye each night.

6. See Your Doctor Once a Year

High blood pressure and elevated blood sugar and cholesterol levels raise your risk of heart disease. But you wont know whether your numbers are high without seeing your family medicine provider or a cardiologist.

To promote good heart health, be sure to take care of yourself and visit your primary care physician at least once a year. Have a discussion with your primary care doctor to see where you are. If your levels are out of range, your doctor may prescribe medications that can help control these risk factors.

About Bingham Healthcare Cardiology

Bingham Healthcares cardiologists are certified to diagnose and treat disorders of the circulatory system and the cardiovascular system the heart, arteries and veins. Using the latest and state-of-the art technology, they provide initial diagnostic services, including basic cardiology evaluations, consultations, stress tests, heart pathology, and arrhythmia detection.

With complete cardiology coverage throughout Eastern Idaho, the following cardiologists are always welcoming new patients.

Call to schedule a consultation in Blackfoot: (208) 785-3897.

Call to schedule a consultation in Idaho Falls: (208) 524-9404.

Call to schedule a consultation in Pocatello: (208) 239-8027.

Dont wait until its too late to treat cardiovascular disease. Youll be glad you did.

Read the original:
Give your heart a makeover - Post Register

Recommendation and review posted by Bethany Smith

From getting first-hand information at our fingertips to interacting with the world around us, it is beyond question how technology affects every area of our lives. Although it offers humanity the platform to access information that is beyond reach, its increased usage can greatly affect our mental health. The associated risks to technology happen when its use is not controlled. Every day, technological advancements keep increasing at the speed of light as breakthroughs in almost every field are a result of it. But, understanding its double-edged impact can greatly influence how we use it. Starting with its negative effects, lets take a look at the various impacts of tech on our mental health.

Adverse Effects of Technology

Sleep Problems

According to Dr. Saju Matthew a board-certified family medicine physician, excessive exposure to bright lights from your smartphone, computer, and tablet can block the secretion of the hormone that helps you sleep. So it is advisable that you set a bedtime and you put away your phone and other smart devices that can interfere with your sleep as this time approaches. Sleep is very important to our health because it removes toxins that build up while you are awake from your brain, it also allows your body to repair itself. Poor sleep can affect your mood by causing anxiety disorders which weakens your bodys ability to fight diseases.

Are you always eager to know whats up online past your bedtime? You may be suffering from problematic internet use. If you find it difficult to keep up with work demands or your relationships due to your mobile device. This may be a sign that it has taken over your life, and you should see a mental health physician.

Emotional Problems

Although social media connects you to the world. Its prolonged use can disconnect you from family and friends in real life. It can make you feel inadequate and dissatisfied with your life when you compare your achievements to others. These negative emotions can affect your mood in a bad way by making you feel stressed and anxious. These symptoms will further increase your addiction to social media and the cycle continues if you dont seek medical help on time. If you discover that your use of social media is making you angry, aggressive, or distracted, you need to control your use of it by reducing time spent online. Also, in a situation where you suffer from cyberbullying or you find yourself doing crazy things to get likes and shares, you need to re-access your use of social media.

Digital Eye Strain

Do you experience eye discomfort when viewing digital screens for extended periods? You may be having digital eye strain. Digital eye strain goes along with symptoms such as dry eyes, itchy eyes, blurry vision, headache, difficulty in concentrating when reading, and increased sensitivity to light. Other factors are bad lighting, screen glare, and bad viewing distance. A poor vision can affect your daily tasks and even your social life which in turn will affect your mental health. To relieve your eyes from strain, reduce your screen time, and adjust the lighting around you.

Musculoskeletal Problems

According to a study, using smartphones for extended hours can cause problems in the nerves, joints, tendons around the shoulders and arm resulting in musculoskeletal disorders. Leaning forward when using a smartphone can stress your neck, spine, and shoulders. You can also experience repetitive stress injuries around the wrist and arms. Repetitive stress injury occurs when you stress the same muscles over time through bad posture. Symptoms include swelling, stiffness, weakness, numbness, and pain ranging from mild to severe. With this disorder, carrying out your daily activities can become a problem. It can lead to depression if you dont get social support on time.

If you are feeling pain from the use of technology, maintaining a proper posture while working and taking frequent breaks to stretch will reduce these issues but if symptoms persist, see a physician.

Children and Technology

Adults are not the only ones that suffer from the negative use of technology, technology affects the mental health of children and teenagers too because they spend a lot of time watching television, playing video games, and using tech toys. Too much screen time can cause sleep problems and behavioral problems in children. Low academic performance and creativity have been associated with children who overuse technology. To control the negative effect of technology on children and teens, use the American Academy of Pediatrics screen time recommendation as a guide:

-Reduce the amount of time spent watching educational programs for children between 18 24 months.

-For children between ages 2-5 years, reduce non-educational programs to 1 hour per weekday and 3 hours during weekends.

-Incorporate healthy screen habits for children between ages 6 and older.

-Use the screen to build creativity and togetherness with family and friends.

-Help your child learn other activities like music, arts, and sports that do not involve a screen.

Positive Effects of Technology

With over 800 apps dedicated to mental health alone, technology has made mental therapy accessible via some mental health apps. Some of these applications provide valuable insights into how you can feel much better whenever you are feeling depressed. They come either free or affordable, making it easier for many people to get.

Many people living in areas far away from their primary care providers can access online treatment in a timely fashion. While using smartphone apps cannot be compared to doctor-to-patient physical consultation, they provide vital information to mental health professionals.

Imagine a world without technology. Navigating physical interactions and mental wellbeing will have been impossible especially in a time like this when various lock-down restrictions are put in place to reduce the spread of the coronavirus. The pandemic increased online engagements across various social media platforms. And most importantly, it has offered avenues for many websites to provide social support.

Optimizing the Use of Technology to Boost Mental Health?

You need no soothsayer to predict that technology will continue to change the world. Rather than exploit it to the point where it becomes harmful to your health, you can explore new ways to maximize its power to improve your health. This can be achieved by using wearable devices, telehealth, and health apps while you enjoy the bond that comes with spending time with real-life friends.

Read the original:
The Effects of Technology on Mental Health - Thrive Global

Recommendation and review posted by Bethany Smith